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Abstract
Gait speed is a marker of health and independence in older adults. Mitigation of gait speed
impairments through intervention on modifiable risk factors is key to preventing adverse
health declines. Using cross-sectional data from adults aged 45 to 85 years in the Canadian
Longitudinal Study on Aging, this thesis estimated population gait speed norms and ‘slow
gait’ prevalence and assessed the potentially modifiable and non-modifiable correlates of gait
speed. Significantly slower average gait speeds and greater proportions of gait speeds below
1.0 m/s were seen in older age groups. While gait speed variability was largely explained by
non-modifiable factors, statistically significant associations were found for several clinical
and lifestyle factors that are modifiable through intervention and education. These findings
were corroborated by our systematic review on the modifiable risk factors for slow gait speed
in older community-dwellers. Future longitudinal research is required to explore the clinical
relevance of these findings.

Keywords
gait speed; older adults; community-dwellers; risk factors; Canadian Longitudinal Study on
Aging
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Summary for Lay Audience
Gait (walking) speed is a marker of health and independence in older adults. Slow gait has
been linked to a greater risk of falls, dependence in everyday activities, multimorbidity,
cognitive decline, and mortality. To prevent and delay gait speed slowing and these negative
outcomes, it is important to target risk factors that can be changed through clinical
intervention and lifestyle modification. Using the cross-sectional data of adults aged 45 to 85
years in the Canadian Longitudinal Study on Aging, this thesis estimated population gait
speed norms and the proportion of individuals with ‘slow gait’ and assessed the potentially
modifiable and non-modifiable factors associated with gait speed. Significantly slower
average gait speeds and greater proportions of gait speeds below 1.0 m/s were seen in older
age groups. While gait speed variability was largely explained by non-modifiable factors,
statistically significant associations were found for several potentially modifiable clinical and
lifestyle factors. These findings were corroborated by our systematic review on the
modifiable risk factors for slow gait speed in older community-dwellers. Future longitudinal
research is required to explore the clinical relevance of these findings.
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Chapter 1

1 Introduction
1.1 Overview
The purpose of this chapter is to provide background information about the main topics
of this thesis. The objectives and hypotheses of the studies as well as an overview of
subsequent chapters will also be provided.

1.2 Biology of Gait
Gait is an essential function for humans that allows for movement through ever-changing
environments with variable terrains. The production, maintenance, and adaptability of
gait involves a complex interplay among multiple physiological and anatomical systems
associated with locomotion. These pathways are typically influenced by additional
factors outside of the locomotor system including neuropsychological factors and agerelated declines in health and physical function.1,2
Early descriptions of the production of rhythmic gait movements suggested that it was an
automatic motor task regulated solely by neural inputs from structures such as central
pattern generators.3,4 This belief, however, was challenged by the discovery that higherorder structures in the central nervous system significantly influence gait production as
well. Under this revised mechanism, aspects of automaticity in gait production are
acknowledged, but the ability to maintain and adapt one’s gait in response to the
perception of environmental stimuli is explained to be the result of coordinated
communication among multiple brain regions associated with cognitive functions such as
executive function, attention, and memory.5–8 Greater demands are placed on these
functions in response to multitasking conditions that involve performing additional tasks
while simultaneously walking.9 If the control of these complex cognitive functions
becomes impaired, the allocation of necessary resources to effectively adjust one’s motor
behaviours in response to multiple tasks and stimuli is limited and abnormalities in gait
performance can arise.10

2

1.3 Gait Speed Analysis
The act of walking can be described through the measurement of several spatiotemporal
and biomechanical parameters including stride length, cadence, support time, and gait
speed.11,12 The analysis of these parameters in real-time has not only contributed to the
understanding of usual gait but has also advanced efforts aimed at exploring the nature of
gait impairments and their association with morbidity over the lifespan. Gait speed
specifically has been recognized as an important measure of physical function as well as
an indicator of health status and future well-being.13 Methods of measuring gait speed
include both manual and electronic techniques. For example, many gait speed tests
involve individuals walking a prespecified distance while their time to cover this distance
is measured using a stopwatch. Other more sophisticated methods can include the use of
electronic walkways that record gait speed digitally.14 Currently, a variety of different
distances are employed for walking tests, with shorter distances between 4 meters and 10
meters most commonly used.15 While a consensus on a standard protocol for walking test
distance has not yet been adopted, tests with variable distances are thought to produce
comparable results after being standardized to meters per second (m/s).15,16

1.4 Adverse Outcomes Associated with Slow Gait Speed
Analyses of gait in healthy individuals using the assessment tools described above have
demonstrated that gait speed typically remains constant over early and middle
adulthood.17,18 Average usual gait speeds among healthy adults aged 20 to 60 years
generally range between approximately 1.30 m/s to 1.45 m/s for men and 1.20 m/s to
1.40 m/s for women.17 While declines in gait speed due to the biological effects of aging
are expected once individuals reach older adulthood, the development of slower gait
speed below the normal threshold, regardless of age, is indicative of possible underlying
health problems.19
The association between slow gait and adverse outcomes is well documented. For
example, adults who walk at slower paces face a greater risk of falls and musculoskeletal
injuries,20,21 morbidity,22–24 and premature mortality.25,26 Current guidelines have detailed
general gait speed ranges and rates of clinically meaningful decline in gait speed that are
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commonly associated with aspects of functional independence and health. In general,
individuals with gait speeds of 1.0 m/s or faster have the highest functional independence
and the lowest risk of experiencing adverse outcomes, however as gait speed declines
below 1.0 m/s, issues are more likely to arise.27 Namely, adults with gait speeds slower
than 0.8 m/s, and especially slower than 0.6 m/s, frequently face mobility impairments
and are more likely to fall, be hospitalized, and even be discharged to nursing care
facilities.27,28 In terms of quantifying declines in speed over time, annual declines ranging
between 0.05 m/s and 0.1 m/s are also used as clinically meaningful indicators of health
status.29

1.5 Risk Factors of Slow Gait Speed
As slow gait is quite prevalent among older adults and can have drastic impacts on
wellbeing,30 there is a pressing need to better understand its etiology so that effective
intervention strategies can be developed and implemented in at-risk populations. Current
understanding from the literature is that gait speed is influenced by a complex set of
factors, which may vary between different populations of adults. These factors can be
classified generally as non-modifiable and potentially modifiable. Risk factors that are
non-modifiable include individual characteristics that cannot be intervened upon such as
age, sex, and height. Conversely, risk factors that are considered potentially modifiable
can be altered, managed, and/or prevented through clinical intervention and lifestyle
changes. While gait speed can be significantly influenced by both types of factors, the
factors that can be modified or prevented are especially important to efforts to mitigate
slow gait and its negative effects in clinical and public health practice.

1.6 Thesis Overview
This thesis is presented in an integrated article format. The content of each chapter is
listed below. Because of this format, some repetition of information is inevitable.
Chapter 2 includes a systematic review with the objective to summarize the potentially
modifiable risk factors that are associated with ‘slow’ and ‘slowing’ gait speed in
community-dwelling adults aged 60 years and older.
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Chapter 3 provides in-depth details on the Canadian Longitudinal Study on Aging
(CLSA) and thorough explanations of the methods employed in the analyses presented in
Chapters 4 and 5.

Chapter 4 examines and compares the gait speed norms of men and women in four 10year age groups as well as the prevalence of slow gait within these strata using baseline
data from the Canadian Longitudinal Study on Aging (CLSA) Comprehensive cohort.

Chapter 5 explores the cross-sectional associations between demographic, clinical,
anthropometric, and lifestyle factors and gait speed among participants in the CLSA
baseline Comprehensive cohort to determine the influence of non-modifiable and
potentially modifiable factors.

Chapter 6 provides a summary and final discussion of the findings presented in the
studies within this thesis. It includes a description of research contributions, study
limitations, and directions for future research.
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Chapter 2

2 Modifiable Risk-Factors for Slow Gait in CommunityDwelling Older Adults: A Systematic Review
A version of this chapter has been submitted for publication.

2.1 Abstract
Purpose: Slow gait speed in older adults is associated with increased risk for falls and
fractures, functional dependence, multimorbidity, and even mortality. The risk of these
adverse outcomes can be reduced by intervening on potentially modifiable risk factors.
The purpose of this systematic review was to identify potentially modifiable risk factors
associated with slow gait speed and clinically meaningful gait speed decline in older
community-dwelling adults.
Methods: Literature searches were conducted in MEDLINE, EMBASE, CINAHL,
Google Scholar, and in the bibliographies of retrieved articles.
Results: Forty studies met the inclusion criteria for qualitative review. Study designs
were cross-sectional and longitudinal. Operational definitions of ‘slow gait’ and
‘meaningful gait speed decline’ were variable and based on sample distributions (e.g.
quartiles), external criteria (e.g. < 0.8 m/s), and dynamic changes over time (e.g. ≥ 0.05
m/s decline per year). Twenty-six potentially modifiable risk factors were assessed in at
least two studies. The risk factors most commonly investigated and that showed
significant associations with slow gait and/or meaningful gait speed decline include
physical activity, education, body mass index, pain, and depression/depressive symptoms.
Conclusion: Among older community-dwellers, potentially modifiable factors such as
physical activity, education, body mass index, pain, and depression/depressive symptoms
have been associated with slow or declining gait speed. Methods used to operationalize
these outcomes must be considered when assessing risk factor effects. Our results suggest
that there are modifiable targets to maintain gait speed that should be examined further in
future investigations.
Keywords: gait speed, aging, systematic review, epidemiology
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2.2 Introduction
Impairments in mobility are prevalent among older adults.1 In particular, slow gait speed
has garnered much attention due to its association with negative health outcomes
including falls, musculoskeletal injuries, comorbidities, and mortality.2–6 Slow gait is also
a marker of general functionality and is linked with overall well-being and the ability to
participate independently in daily activities.7
The causes of slowing gait speed with aging are understood to be multi-factorial.8
Analyses of gait function across the adult lifespan have shown associations between
several non-modifiable risk factors and declines in gait speed, with aging being one of the
strongest predictors of such decline.9,10 Due to the impact of slow gait on individuals’
health and quality of life and its ability to predict future deterioration of health, research
interest is shifting towards identifying potentially modifiable causes of gait speed decline
and slow gait speed. In contrast to non-modifiable factors that are unalterable such as age
and sex at birth, modifiable risk factors can potentially be altered and/or managed
through various methods including clinical treatment and lifestyle changes. By
identifying and intervening on these factors, diagnosis and treatment strategies can be
improved to mitigate further morbidity and disability associated with gait speed
impairment in at-risk populations.11
Previous systematic reviews have explored the influence of cognitive function on gait
speed in aging populations.12,13 However no systematic review has yet provided a
comprehensive review of non-cognitive related factors associated with slow gait speed or
clinically meaningful gait speed decline that could potentially be modified to prevent
progressive declines in this motor function. Therefore, the aim of this systematic review
was to identify potentially modifiable clinical and lifestyle factors associated with slow
gait speed and clinically meaningful gait speed decline in older community-dwelling
adults.
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2.3 Methods
2.3.1 Inclusion and Exclusion Criteria
Studies were included if they met the following inclusion criteria: 1) sample of
community-dwelling adults in any country, 2) subjects aged 60 years and older on
average, 3) assessment of usual, or self-selected, gait speed as an independent physical
function through face-to-face assessment using any measured time and distance walk test,
4) clearly stated operational definition (criteria or cutoff) of slow gait or clinically
meaningful decline in gait speed, 5) investigation of at least one potentially modifiable
risk factor for slow gait or clinically meaningful decline in gait speed, and 6)
observational study design (cohort, cross-sectional, case-control).
Studies were excluded under the following conditions: 1) mean age of subjects under 60
years, 2) subjects were hospitalized, institutionalized, or sampled because of diagnosis of
specific clinical conditions (e.g. Parkinson’s disease or stroke), 3) assessment of risk
factors using only composite outcome measures of physical function (e.g. frailty), 4)
measurement of gait speed from treadmill walking, walking on non-flat surfaces, or other
tests of ambulation (e.g. Dual-Task tests, Timed Up and Go test), or 5) intervention
studies to improve physical functioning. Non-peer reviewed articles, systematic reviews,
meta-analyses, randomized trials of interventions, case report and series, ideas, editorials,
opinions, and animal research studies identified in the bibliographic search were also
excluded.

2.3.2 Search Strategy
Article searches were performed in June 2019 in MEDLINE, EMBASE, and CINAHL.
The search strategy was developed through consultation with a research librarian at
Western University (Marisa Tippett) using MeSH and keyword terms that are related to
the main elements of the research question. Key terms included walking speed, slow gait,
aged, and community-dwelling (see Appendix 1 for full search strategy and results). No
publication date or language restrictions were applied, and no comparison group was
identified due to the exploratory nature of the review. Furthermore, searches in Google
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Scholar using key terms and searches through the reference lists of the relevant articles
were performed.

2.3.3 Study Screening and Selection
Articles retrieved from the online searches were exported into the Mendeley citation
manager. After removing duplicates, level 1 screening of titles and abstracts of the
potentially eligible articles was completed by one independent reviewer (EF). For level 2
screening, the full texts of articles selected from level 1 were retrieved and independently
assessed for eligibility by two co-authors (EF and FF). Disagreements about study
eligibility were discussed and resolved between EF and FF. Disagreement about study
eligibility not resolved between EF and FF were taken to senior authors of this study (MS
and MMO) for final decision.

2.3.4 Data Extraction
Data extraction was completed by one reviewer (EF). The information extracted included
author, year of publication, study design and location, participant characteristics, method
of gait speed measurement, criteria used to define slow gait or clinically meaningful
decline in gait speed, and main statistical findings including identified risk factors. If any
information was not provided, “NR” (Not Reported) was inputted into the corresponding
section.

2.3.5 Risk of Bias Assessment
The methodological quality of the included studies was assessed by two independent
reviewers (EF and FF) using the “Quality Assessment Tool for Observational Cohort and
Cross-Sectional Studies” developed by the National Heart, Lung, and Blood Institute
(NIH).14 This tool comprises 14 items to evaluate aspects of internal validity of
observational studies including selection bias, information and measurement bias, and
confounding. Each item could be given one of the following ratings: Yes, No, Not
Applicable, Not Reported, or Cannot Determine. Studies were given a quality rating
based on the number of items met using the NIH guidelines and then categorized as
“good” [met 10-14 criteria], “fair” [met 5-9 criteria], or “poor” [met 0-4 criteria].15
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Disagreements about scoring for each item were discussed and resolved between the
reviewers. A summary of overall study ratings is provided in Table 2-1.

2.3.6 Synthesis of Results
In this quantitative systematic review, the data extracted from the selected articles were
tabulated to allow for a synthesis of the findings that included summaries and
comparisons of participant characteristics, outcome assessments, and overall trends of
main findings. Meta-analyses of risk factor effects were not conducted due to
heterogeneity in outcome cut-offs and lack of evidence for many factors.

2.4 Results
2.4.1 Study Quality and Characteristics
Forty articles published between 2006 and 2019 were included in this review; 21 were
cross-sectional while 19 were longitudinal, with reported follow-ups ranging from 1 to 12
years. Most studies were performed in North American (14/40) and Asian (11/40)
countries, with the remaining studies from Europe, South America, the Middle East, and
Australia. The overall quality of each article is summarized in Table 2-1. Briefly, 15
studies were rated as ‘Good’ and 25 were rated as ‘Fair’. The cross-sectional studies
generally achieved lower scores as their design inherently prohibited the assessment of a
temporal relationship between the exposures and outcome. All studies reported the use of
valid measurement tools to assess the variables of interest and most accounted for
important covariates in their analyses. Sample size or power justification and blinding of
study assessors was reported in less than a quarter of the studies. The full quality
assessment for all articles is provided in Appendix B.
Sample sizes ranged from 108 to 7025 and the proportion of female participants ranged
from 0% to 100%. Usual (i.e. self-selected) gait speed was measured in all studies, with
walking test distances ranging from 2.4 meters to 20 meters. The most common walk test
distances employed were 6 meters (9/40), 4 meters (7/40), 4.6 or 5 meters (7/40), 3
meters (6/40), and 20 meters (4/40). Distances less than 3 meters were reported in three
studies, while those between 7 and 20 meters were reported in the remaining studies.
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Criteria to define individuals as having slow gait or clinically meaningful decline in gait
speed were reported in all studies but were noticeably inconsistent. The studies used a
mix of relative (e.g. sample distribution-based, such as lowest quartile) and absolute (e.g.
external criterion, such as less than 0.8 meters per second) cutoffs, as well as measures of
changing gait speed (e.g. decline of 0.05 meters per second per year). Relative and
absolute cutoffs were seen in both cross-sectional and longitudinal analyses while
measures of changing gait speed could only be used in studies that assessed gait speed on
multiple occasions over time. The most commonly used sample distribution-based
criteria for slow gait were lowest quintile (8/40) and lowest quartile of gait speed (6/40)
with various adjustments for factors such as age, sex, and height, and ≥ 1 standard
deviation below age and sex gait speed means (3/40). The most common external
criterion cutoffs for slow gait were < 0.8 m/s (7/40) and < 1.0 m/s (6/40). In the
longitudinal studies, the most common definitions of significant declines in gait speed
were ≥ 0.05 m/s decline per year (3/40) and ≥ 0.1 m/s decline per year (2/40). These
heterogeneous measures resulted in a wide range of prevalence of slow gait in the 17
cross-sectional studies, with the frequency ranging between 1.56% to 65.8%. Among the
longitudinal studies, 17 reported the frequency of participants who experienced a
clinically meaningful decline in gait speed at follow-up. A full summary of study
characteristics and findings can be found in Appendix C (Tables C-1 and C-2).
Table 2-1. Quality of studies included in review.
Author

Year

Quality*

Kyrdalen et al.16

2019

Fair

Montero-Odasso et al.17

2019

Good

Nasimi et al.18

2019

Fair

Toyama et al.19

2019

Good

Laclaustra et al.20

2019

Good

Kwan et al.21

2019

Fair

Lassale et al.22

2019

Good

Xu et al.23

2019

Fair

Umegaki et al.24

2018

Fair
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Adachi et al.25

2018

Fair

Simonsick, Aronson et al.26

2018

Good

Taylor et al.27

2018

Fair

Simonsick, Schrack et al.28

2018

Good

Ayers et al.29

2017

Good

Shafie et al.30

2017

Fair

Veronese et al.31

2017

Fair

Yokoyama et al.32

2017

Fair

Gill et al.33

2016

Good

Garcia-Esquinas et al.34

2016

Fair

Naples et al.35

2016

Good

Zeng et al.36

2016

Fair

Verghese et al.37

2016

Good

Plouvier et al.38

2016

Fair

Rosano et al.39

2016

Fair

Frison et al.40

2015

Fair

Tchalla et al.41

2015

Fair

Kirkness et al.42

2015

Fair

Lo-Ciganic et al.43

2015

Good

Busch et al.44

2015

Fair

Kim et al.45

2015

Good

Lana et al.46

2015

Fair

Leon-Munoz et al.47

2014

Good

Wu et al.48

2013

Fair

Ruggero et al.49

2013

Fair

Hirani et al.50

2013

Fair

Thorpe et al.51

2011

Good

Eggermont et al.52

2010

Fair

Yoshida et al.53

2010

Fair

Shardell et al.54

2009

Fair
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Chu et al.55

2006

Good

*NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies

2.4.2 Factors Assessed for Association with Gait Speed
A total of 85 potentially modifiable risk factors were studied. Refer to Appendix C
(Tables C-1 and C-2). Of the 85 factors, 26 were found in at least two studies. As
summarized in Table 1-2, the most commonly assessed factors include physical activity
(10/40), body mass index (10/40), education level (7/40), pain (6/40), heart conditions
(6/40), and depression/depressive symptoms (5/40). Each study tested associations at the
five percent level of significance and the proportion of studies that reported statistically
significant findings for each factor ranged from zero to 100 percent. All studies that
examined education level, polypharmacy, calf circumference, digit symbol substitution
test, and Mediterranean diet reported statistically significant effects. Other factors with
statistically significant effects reported in less than 100 but at least 50 percent of studies
included pain, depression/depressive symptoms, falls, fear of falling, arthritis, grip
strength, impaired vision, physical activity, body mass index, bone mineral density, high
sensitivity C-Reactive protein, and albumin. Results should be interpreted with caution
because statistical significance can be influenced by sample size and statistically
significant effects may not necessarily be clinically meaningful.
Table 2-2. Summary of risk factors assessed in at least two studies.
Factor Classification

Factors assessed in ≥
2 studies

Sociodemographic

Education Level

Clinical

Pain
Heart Conditions
Depression/Depressive
symptoms
Multimorbidity
Hypertension
Stroke
Falls
Arthritis
Grip Strength
Diabetes

No. Studies that
included the
factor
7/40

No. (%) Studies
reporting significant
factor effects
7/7 (100%)

6/40
6/40
5/40

5/6 (83.3%)
2/6 (33.3%)
4/5 (80%)

4/40
4/40
4/40
4/40
4/40
3/40
3/40

1/4 (25%)
1/4 (25%)
1/4 (25%)
3/4 (75%)
2/4 (50%)
2/3 (66.7%)
0/3 (0%)
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Polypharmacy
Fear of Falling
Impaired Vision

2/40
2/40
3/40

2/2 (100%)
1/2 (50%)
2/3 (66.7%)

Lifestyle

Physical Activity
Smoking
Alcohol Consumption

10/40
3/40
3/40

9/10 (90%)
0/3 (0%)
1/3 (33.3%)

Body Composition

Body Mass Index
Calf Circumference
Bone Mineral Density

10/40
2/40
2/40

8/10 (80%)
2/2 (100%)
1/2 (50%)

Serum

Vitamin D
High Sensitivity CReactive Protein
Albumin

3/40
2/40

1/3 (33.3%)
1/2 (50%)

2/40

1/2 (50%)

Digit Symbol
Substitution
Trail Making Test

2/40

2/2 (100%)

2/40

0/2 (0%)

Mediterranean Diet

2/40

2/2 (100%)

Cognition

Dietary

2.4.2.1 Sociodemographic Factors
Education Level: Seven studies examined education as a contributor to slow gait speed or
clinically meaningful decline in speed.16,23,27,30,42,44,51 Xu et al. and Taylor et al. reported
significantly reduced odds of slow gait for individuals with more than a high school
education (OR=0.85, 95% CI=0.78; 0.93 and OR=0.49, 95% CI=0.36; 0.66 respectively).
Taylor et al. further found a non-significant result for individuals with high school
education only. In terms of being less educated, significantly increased odds of slow gait
or clinically meaningful speed decline for individuals with 10 or fewer years of education
were reported by Kyrdalen et al., Shafie et al., and Busch et al. with ORs ranging from
2.69 to 3.58. Additionally, Kirkness et al. reported significantly greater odds of slow gait
for those with high school education or less, while Thorpe et al. reported a significantly
greater odds of meaningful speed decline among women with less than 9th grade reading
level abilities. Finally, Busch et al. and Shafie et al. reported significantly higher odds of
slow gait among adults who were illiterate or who had no formal education (OR=3.20,
95% CI=NR and OR=5.11, 95% CI=2.04; 12.79 respectively).
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Other Factors: Other sociodemographic risk factors for slow gait or clinically
meaningful speed decline that were only identified in single studies were occupation,38
not owning a home,51 and low annual income.42 Protective factors identified in single
studies were access to medical care and being an urban resident.36,42

2.4.2.2 Clinical Factors
Depression and Depressive Symptoms: The association between slow gait and depression
or depressive symptoms was estimated in five studies.16,25,29,37,42 Using scores on
modified versions of the Center for Epidemiologic Studies Depression Scale or Geriatric
Depression Scale to categorize individuals as having depression or not, Kirkness et al.
and Adachi et al. reported significantly higher odds of slow gait for individuals with
depression (OR=1.97, 95% CI=1.35; 2.87 and OR=2.73, 95% CI=1.12; 6.68
respectively), while Verghese et al. reported a non-significant association for those with
depression (RR=1.19, 95% CI=0.84; 1.69). Furthermore, Kyrdalen et al. found
significantly greater odds of slow gait for individuals with more depressive symptoms
and Ayers et al. reported greater risk of developing slow gait among individuals with
symptoms of apathy.
Pain: Six studies examined the relationship between slow gait speed or clinically
meaningful speed decline and pain.26,27,37,42,45,52 Taylor et al. and Verghese et al. found
that recent or frequent experience of pain in general was significantly associated with
slow gait (OR= 1.38, 95% CI=1.11; 1.73 and RR=1.45, 95% CI=1.11; 1.89), however
Kim et al. reported a non-significant association for pain (OR=0.76, 95% CI=0.45; 1.31).
In addition, Eggermont et al. reported significantly greater odds of slow gait for
individuals with higher tender point counts but did not find a significant association for
single, multi-site, or widespread pain. In terms of specific pain sites, Kirkness et al. and
Kim et al. found that knee pain significantly increased the odds of slow gait (OR=1.43,
95% CI=1.02; 2.01 and OR= 1.73, 95% CI=1.08; 2.76 respectively). Kirkness et al.
additionally reported a significant effect for back pain on slow gait (OR=1.45, 95%
CI=1.05; 2.01), however Simonsick et al. reported non-significant associations for lower
limb and joint pain.
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Multimorbidity: Measures of multimorbidity were included as potential predictors of
slow gait speed or clinically meaningful speed decline in four studies.16,27,36,51 Only
Taylor et al. reported significant results for increased odds of slow gait in people with
two comorbidities (OR=1.54, 95% CI=1.12; 2.11) and in those with three or more
comorbidities (OR=2.18, 95% CI=1.48; 3.20). Contrarily, Zeng et al. found that having
two or more comorbidities was not a significant predictor in their stepwise regression
model for slow gait, and Kyrdalen et al. reported non-significant associations between
slow gait and having three to four comorbidities or having five to eleven comorbidities
(OR=1.32, 95% CI=0.51; 3.22 and OR=1.41, 95% CI=0.52; 3.43 respectively). Thorpe et
al. also did not find a significant association between having two or more comorbidities
and experiencing clinically meaningful gait speed decline over time in neither men
(OR=1.31, 95% CI=0.97; 1.76) nor women (OR=1.22, 95% CI=0.89; 1.68).
Hypertension: Four studies assessed the association between hypertension and slow
gait.23,37,41,42 Both Kirkness et al. and Verghese et al. reported non-significant effects for
hypertension (OR=1.41, 95% CI=0.96; 2.09 and RR= 0.98, 95% CI=0.70; 1.38
respectively). Xu et al. also did not find a significant effect (values not reported).
However, in their assessment of the relationship between circulating vascular cell
adhesion molecule-1 and slow gait, Tchalla et al. found a significant interaction effect
between this vascular-related molecule and hypertension on slow gait as compared to
normotensive individuals (OR= 3.01, 95% CI=1.56; 5.83).
Heart conditions: The association between slow gait and various heart conditions was
examined in six studies.23,37,38,42,44,45 Two of these studies created composite variables for
cardiovascular conditions. First, using a composite variable that included angina,
myocardial infarction, and cardiac failure, Verghese et al. found that having a heart
condition did not significantly predict developing slow gait in the future (RR=1.01, 95%
CI=0.74; 1.39). Second, using a different composite variable for cardiovascular disorder
that included diagnosis of hypertension, arteritis, coronary heart disease, and stroke,
Plouvier et al. found that having a cardiovascular disorder was not significantly
associated with slow gait in women, but was among men (OR= 2.09, 95% CI=1.22;
3.58). Using single heart condition variables, Busch et al. reported that individuals with
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cardiovascular disease were approximately twice as likely to have slow gait, while Kim et
al. did not find a significant association between heart disease and slow gait (OR=1.30,
95% CI=0.74; 2.30). Xu et al. also did not find a significant effect for heart disease.
Finally, Kirkness et al. reported no significant effect for heart failure alone on having
slow gait.
Stroke: Four studies assessed the association between history of stroke and slow
gait.23,37,42,49 Using a cross-sectional design, Ruggero et al. reported significantly greater
odds of slow gait for those who have experienced a stroke (OR= 3.41,
95% CI=1.31; 8.86), however no significant relationships between history of stroke and
slow gait were found by Kirkness et al. or Xu et al. Verghese et al. also reported a nonsignificant effect for stroke history using a longitudinal analysis.
Polypharmacy: The relationship between polypharmacy and slow gait or clinically
meaningful speed decline was measured in two studies.16,17 Montero-Odasso et al.
reported significantly increased odds of slow gait for more medications taken both crosssectionally and longitudinally (OR=1.27, 95% CI=1.13; 1.42 and OR= 1.21, 95%
CI=1.10; 1.32 respectively) and found that the risk of developing slow gait over time was
more than three times higher for individuals with polypharmacy. Additionally, Kyrdalen
et al. found significantly greater odds of slow gait for those taking 6 to 17 medications
(OR= 4.28, 95% CI=1.63; 11.2) but not for those taking less than six medications.
Falls and Fear of Falling: Four studies examined falls and two studies examined fear of
falling as potential predictors of slow gait or meaningful decline in gait speed.16,37,45,49,55
Both Verghese et al. and Chu et al. reported significant associations between recent fall
history and incidence of slow gait or meaningful speed decline (RR= 1.32, 95% CI=1.04;
1.66 and RR= 2.42, 95% CI=1.53; 3.83 respectively). Contrarily, Kim et al. did not find a
significant association between experience of any falls and slow gait (OR=1.78, 95%
CI=0.82; 1.86). Furthermore, Kyrdalen et al. found that recent history of multiple falls
was linked to significantly greater odds of slow gait (OR= 3.70, 95% CI=1.18; 11.65),
however no effect was seen for previous experience of a single fall. Lastly, Kyrdalen et
al. did not find a significant association between fear of falling and slow gait (OR= 1.84,
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95% CI=0.84; 4.02), however Ruggero et al. showed significantly greater odds of slow
gait for individuals who reported being fearful of falling (OR= 2.27, 95% CI=1.21; 4.24).
Grip Strength: The association between grip strength and slow gait was examined in
three studies.25,37,44 Using grip strength values one or more standard deviations below age
and sex means to categorize individuals as having muscle weakness, Verghese et al.
reported a significantly greater incidence of slow gait for individuals classified as weak
compared to non-weak (RR=1.48, 95% CI=1.07; 2.05). Using grip strength as a
continuous measure, Adachi et al. found grip strength to be inversely associated with
slow gait (OR=0.82, 95% CI=0.73; 0.93), however a significant relationship was not
found by Busch et al.
Arthritis: Measures of arthritis were assessed as potential predictors of slow gait speed or
clinically meaningful speed decline in four studies.37,42,45,51 Kirkness et al. reported
significantly greater odds of slow gait for individuals with clinically diagnosed knee
osteoarthritis (OR=2.06, 95% CI=1.47; 2.89), while Thorpe only found a significant
association for self-reported knee osteoarthritis among women (OR= 1.78, 95% CI=1.18;
2.69). Kim et al. reported a non-significant effect for self-reported knee osteoarthritis on
slow gait (OR=1.19, 95% CI=0.67; 2.10). Lastly, Thorpe et al. reported a non-significant
effect for hip osteoarthritis and Verghese et al. did not find a significant association
between self-report of any type of arthritis and incidence of slow gait (RR=1.05, 95%
CI=0.71; 1.53).
Diabetes: All three studies that examined the relationship between diabetes and slow gait
reported non-significant associations.23,37,42
Impaired Vision: Three studies assessed the relationship between vision impairment and
slow gait.16,37,55 While Kyrdalen et al. did not find a significant association (OR=1.54,
95% CI=0.70; 3.40), Verghese et al. reported significantly greater risk of incident slow
gait for those with poor vision (RR= 1.36, 95% CI=1.02; 1.89). Chu et al. also found poor
visual acuity to be significantly associated with meaningful gait speed declines
(RR=2.41, 95% CI=1.22; 4.78).
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Other Clinical Factors: Other clinical risk factors for slow gait or clinically meaningful
speed decline only identified in single studies were metabolic syndrome,23
musculoskeletal disorders,38 lung disease,42 cancer,42 disability,30 hyperuricemia,31
urinary incontinence,49 and fatigability.28 Other singularly identified clinical factors that
did not have a significant association with slow gait or meaningful decline were statin
use,43 drug interactions,35 hyperlipidemia,45 COPD,44 asthma,42 tumor,23 dyslipidemia,23
renal function,19 self-rated health,36 ulcer,42 tiredness and energy level,28 and
osteoporosis.45

2.4.2.3 Lifestyle Factors
Physical Activity: The relationship between level of physical activity and slow gait was
examined in ten studies.19,23,25,30,36–38,44,45,49 Seven of these studies found significantly
lower odds of slow gait among those who reported being physically active in some way,
with ORs ranging from 0.27 to 0.94. Plouvier et al. reported significantly lower odds only
for individuals who engaged in recreational activities for more than two hours per week
and Kim et al. did not find a significant association between regular exercise and slow
gait (OR= 0.79, 95% CI=0.50; 1.26). In terms of physical inactivity, both Verghese et al.
and Ruggero et al. reported significantly greater likelihood of slow gait for individuals
who were not physically active (RR= 1.94, 95% CI=1.20; 3.12 and OR=2.24, 95%
CI=1.18; 4.25 respectively).
Smoking: Three studies included smoking as a potential predictor of slow gait.23,36,38
None of these studies found smoking to significantly influence the odds of having slow
gait.
Alcohol Consumption: Three studies included alcohol consumption as a potential
correlate of slow gait.23,36,37 While Xu et al. reported significantly lower odds of slow gait
for those who consumed alcohol (OR= 0.71, 95% CI=0.54; 0.95), Zeng et al. and
Verghese et al. found no significant association between alcohol consumption and
likelihood of slow gait.
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Other Lifestyle Factors: Other lifestyle factors that were associated with slow gait but
were only identified in single studies were unstructured daily routine and impaired
activities of daily living.36,44 Other singularly identified clinical factors that did not have a
significant association with slow gait were hours of sleep and poor sleep quality.23,37
Finally, factors identified in single studies that showed a protective effect were hobby
engagement,36 social networking,30 social participation,21 and life-space.21

2.4.2.4 Body Composition Factors
Body Mass Index (BMI): The association between BMI and slow gait or clinically
meaningful speed decline was examined in ten studies.16,18,23,33,36–38,42,45,51 Using BMI as a
continuous measure, Zeng et al. reported a significant positive association between BMI
and slow gait speed (OR=1.25, 95% CI=1.09; 1.43), while Xu et al. and Kyrdalen et al.
did not find a significant association. Using normal BMI as a reference, both Nasimi et al.
and Kim et al. reported significant associations between underweight BMI and greater
odds of slow gait (OR= 5.22, 95% CI=1.35; 20.12 and OR=1.25, 95% CI=1.11; 1.40
respectively). Using non-obese BMI as the reference, Verghese et al. and Plouvier et al.
found a significantly greater likelihood of slow gait among those who were obese
(RR=1.35, 95% CI=1.07; 1.69, OR=2.34, 95% CI=1.14; 4.81 [men], and OR=3.31, 95%
CI=1.35; 8.13 [women] respectively), while Thorpe et al. found a significant effect for
obesity only among women (OR=1.36, 95% CI=1.01; 1.83). Plouvier et al. further
reported no significant effect for overweight BMI as compared to normal BMI in neither
men nor women. Next, using normal weight as the reference, Gill et al. found that
individuals with overweight BMI and those with obese BMI were at significantly greater
risk of having slow gait (RR=1.3, 95% CI=1.0; 1.7 and RR=2.1, 95% CI=1.6; 2.7
respectively), and when also incorporating waist circumference into their analyses, they
reported that only those who were overweight or obese in the largest waist circumference
category had a significantly increased the risk of slow gait as compared to those in the
smaller waist categories. Lastly, Kirkness et al. found significantly lower odds of slow
gait for those considered healthy, underweight, or overweight as compared to those
considered obese (OR= 0.55, 95% CI=0.36; 0.85 and OR= 0.48, 95% CI=0.34; 0.69
respectively).
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Calf Circumference: Two studies measured the association between calf circumference
and slow gait.18,45 Both Nasimi et al. and Kim et al. reported significantly reduced odds of
slow gait with increased calf circumference (OR= 0.82, 95% CI=0.72; 0.92 and OR=
0.81, 95% CI=0.72; 0.92 respectively).
Bone Mineral Density: Two studies included bone mineral density as a potential predictor
of slow gait.23,45 Kim et al. found that greater bone mineral density was significantly
associated with lower odds of slow gait (OR=0.51, 95% CI=0.32; 0.79), while Xu et al.
did not find bone mineral density to be a significant predictor of slow gait (values not
reported).
Other Body Composition Factors: Another body composition factor that was identified to
impart risk on experiencing slow gait but was only identified in a single study was body
fat.18 Other factors examined in single studies that did not have a significant association
with slow gait were visceral fat area,18 fat-free mass,18 muscle protein,18 bone mineral
content,18 and central adiposity.23

2.4.2.5 Serum Factors
Vitamin D: The association between vitamin D and slow gait was examined in three
studies.45,50,54 Shardell et al. reported significantly greater odds of slow gait for men with
low vitamin D (OR=2.20, 95% CI=1.17; 4.11) but this effect was not seen in women
(OR=1.12, 95% CI=0.59; 2.14). Neither Hirani et al. nor Kim et al. found significant
effects for 25-hydroxyvitamin D on slow gait, however Hirani et al. reported significantly
greater odds of slow gait for individuals in the lowest quartile of 1,25-dihydroxyvitamin
D (OR=1.65, 95% CI=1.05; 2.63).
High Sensitivity C-Reactive Protein (CRP): Two studies assessed the relationship
between CRP and slow gait.22,53 While Yoshida et al. did not find a significant effect for
elevated CRP (OR=1.82, 95% CI=0.94; 3.51), Lassale et al. reported significantly greater
odds of slow gait for individuals with elevated CRP cross sectionally (OR=1.43, 95%
CI=1.03; 1.98) as well as for individuals whose CRP levels increased from medium to
high over follow-up (OR=1.61, 95% CI=1.15; 2.24).
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Albumin: Two studies included albumin as a potential predictor of slow gait.18,45 Kim et
al. reported significantly lower odds of slow gait for higher albumin level while Nasimi et
al. did not find a significant effect (OR=0.17, 95% CI=0.06; 0.46 and OR=1.48, 95%
CI=0.88; 2.46 respectively).
Other Serum Factors: Other serum factors that were identified to impart risk on
experiencing slow gait but were only identified in single studies were plasma fatty
acids,40 high density lipoprotein,45 and cystatin C.45 Other factors examined in single
studies that did not have a significant association with slow gait were triglycerides,18 B2microglobulin,45 hemoglobin A1c,45 and parathyroid hormone.54

2.4.2.6 Cognitive Factors
Digit Symbol Substitution Test (DSST): Two studies assessed the relationship between
scores on the digit symbol substitution test and slow gait.24,39 Both Umegaki et al. and
Rosano et al. found that higher DSST scores were linked to lower odds of slow gait
cross-sectionally (OR= 0.71, 95% CI=0.54; 0.94, OR=0.97, 95% CI=0.97; 0.98
[subclinical gait speed group], and OR= 0.93, 95% CI=0.93; 0.95 [clinical gait speed
group]). Rosano et al. did not find similar significant associations longitudinally.
Trail Making Test (TMT): Performance on the trail making test was assessed for an
association with slow gait in two studies.16,25 Kyrdalen et al. reported a non-significant
association for performance on part B of the TMT with slow gait (OR=1.56, 95%
CI=0.64; 3.83), and Adachi et al. found a non-significant effect for the difference in time
spent between part B and A (OR=1.00, 95% CI=1.00; 1.01).
Other Cognitive Factors: Other cognitive factors that were identified to impart risk on
experiencing slow gait but were only identified in single studies were cognitive
impairment and white matter hyperintensities.37,39 Factors examined in single studies that
did not have a significant association with slow gait were logical memory performance
and Mini Mental State Examination performance.24,25 Lastly, a factor identified in a
single study that showed a protective effect on slow gait was absence of dementia.27
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2.4.2.7 Dietary Factors
Mediterranean Diet: The association between adherence to a Mediterranean diet and
slow gait was examined in two studies.21,47 Kwan et al. reported that individuals whose
Mediterranean diet scores were in the upper two tertiles had significantly lower odds of
slow gait (OR= 0.38, 95% CI=0.17; 0.84 [T2] and OR= 0.17, 95% CI=0.06; 0.44 [T3]).
Leon-Munoz et al. additionally reported that only individuals whose scores on the
Mediterranean Diet Adherence Screener were in the highest tertile had significantly
lower odds of slow gait (OR= 0.53, 95% CI=0.35; 0.79). Leon-Munoz et al. found no
significant effect for Mediterranean Diet Score.
Other Dietary Factors: Other dietary factors that were identified to impart risk on
experiencing slow gait but were only identified in single studies were low fiber intake
and dietary inflammatory index.20,48 Factors examined in single studies that did not have
a significant association with slow gait were energy intake,23 protein intake,23 fruit and
vegetable consumption,34 and meals per day.36 Finally, factors identified in single studies
that showed a protective effect on slow gait were dietary variety and dairy
consumption.32,46

2.5 Discussion
To our knowledge, this is the first systematic review to comprehensively examine a broad
range of potentially modifiable risk factors for slow gait speed and clinically meaningful
decline in gait speed among community-dwelling older adults. Across the 40 studies
included in this review, 85 potentially modifiable risk factors were assessed for an
association with slow gait or clinically meaningful gait speed decline. Of these factors, 26
were examined in two or more studies.
The included studies used cross-sectional and longitudinal designs. More than
half of the studies were given a ‘fair’ quality rating which was mainly influenced by the
simultaneous assessment of exposures and outcomes during the same time periods. The
size of the odds/risk ratios were generally small to moderate and tended to be
heterogeneous. Sources of heterogeneity include differences in exposure measurements,
cutoffs, and the design used. Another major probable reason for the heterogeneity of
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effects is the use of different operational definitions of slow gait and meaningful decline.
The approaches used included relative cutoffs based on the observed distributions of gait
speed in the study samples (e.g. quartiles/quintiles), external criteria (e.g. < 0.8 m/s), and
dynamic measures of change in gait speed over time (e.g. ≥ 0.05 m/s decline per year).
The use of relative cutoffs based on sample distributions has advantages. It is a
transparent and simple use of descriptive statistics to create strata of approximately equal
size. This guarantees a sufficient number of people with the slowest gait speed for
statistical comparisons. This is not assured if an external criterion is used, particularly
with a small sample that was recruited from a group with above-average gait speed.
However, the gait speed cutoff of the slowest quartile will likely differ among samples
recruited from populations with different average gait speeds, which will cause
heterogeneity in odds ratios across studies even if all other variables in all studies are
measured identically. Another problem is that there is no reason to expect an internally
derived lowest quartile cutoff to be close to an external criterion, which will be another
source of heterogeneous findings across studies. Ultimately, while this review is
informative, definitive conclusions should not be made from the evidence currently
presented as the effects for the risk factors were summarized through qualitative
observation only, and insufficient evidence for many factors is present to ensure that the
effect measures are truly reflective of populations beyond the studies.
The three risk factors most commonly investigated among the studies in this review were
physical activity, BMI, and education level. Overall, the effect estimates reported for
each of these factors were mostly consistent and suggested that the likelihood of
experiencing slow gait or clinically meaningful speed decline was decreased for those
who were physically active and increased for those who were obese, underweight, and
less educated. The benefits of regular physical activity on multiple aspects of health
including chronic illnesses, functional capacity, and longevity have been welldocumented.56 In older adults especially, engagement in moderate to high levels of
physical activity has clear benefits for delaying or preventing incident functional
impairments and disability such as slow gait that can reduce independence in everyday
life.57 Conversely, a notably high or low BMI has been associated with a greater risk of
functional declines and incident disability.58 Obesity is associated with the development

27

of comorbidities that contribute to these declines including musculoskeletal conditions,
cardiovascular conditions, and diabetes.59 Being underweight also has potential negative
effects on aspects of physical function in older adults such as muscle strength and may be
linked with nutritional deficiencies that further promote health declines.60,61 Being less
educated may also increase the risk of gait speed impairment in complex ways. Low
socioeconomic status, which includes one’s education level, is a known contributor to the
experience of various health disparities. Low education level specifically has been linked
to a greater risk of adverse outcomes including disability, development of chronic
conditions, and overall poor health.62–65 Individuals with fewer years of education are
also more likely to engage in sedentary lifestyles and unhealthy behaviours.66,67
Additionally, as those with low socioeconomic status frequently face barriers to accessing
healthcare resources,68 their likelihood of receiving care for health declines and
associated physical impairments including slow gait is reduced.
Other factors that also appeared more commonly across the included studies were pain,
depression/depressive symptoms, and heart conditions. Among the results for pain, which
included effect estimates for both general and site-specific measures, an overall trend for
greater likelihood of slow gait was exhibited for those with some type of pain.
Experience of frequent or chronic pain is known to negatively impact multiple domains
of quality of life such as physical function, independence, and psychological wellbeing.69 Pain severity and its association with mobility impairments can additionally be
exacerbated by chronic conditions including musculoskeletal disorders and obesity, and
by other unhealthy behaviours.70 Incidence of disability in functional parameters
including gait can also be magnified by the ways in which individuals think about their
pain, which may involve pain catastrophizing and pain-related fear.71,72 The results for
depression-related effect measures were also fairly consistent in that having depression or
more depressive symptoms increased the likelihood of slow gait. Longitudinal
associations between depression and incident disability have been observed.73,74 While
depression can directly influence physical functioning through biological pathways, this
relationship may also be influenced by other factors that co-occur in those with
depression including multimorbidity and unhealthy lifestyle behaviours.75,76 Conversely,
many of the studies examining heart conditions found a non-significant effect of these
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measures on the likelihood of slow gait speed. As presented in current literature,
components of frailty including slow gait share similar causal pathways with
cardiovascular disease and many studies have identified slow gait as a predictor of
adverse cardiovascular outcomes.77–79 While impairments in motor function may be
independently influenced by the diagnosis of various heart conditions,80,81 other vascular
factors associated with the development of these conditions (e.g. hypertension,
inflammation) could account for the effect that heart conditions appear to have on gait
speed.82 Existence of a potential link between heart conditions and gait speed impairment
does however merit further investigation.
It is important to note that other clinical, behavioural, serological, and cognitive risk
factors were assessed in addition to the factors described above. Many of these factors
may play important roles in the development of slow gait or significant gait speed decline
however our synthesis shows that the evidence available for these factors remains
limited. In order to gain a better understanding of the relationships between these factors
and gait speed, gaps such as those highlighted in this review must be addressed with
additional research.
Overall, it is clear that in older populations, gait speed is influenced by a complex
network of biological, mechanical, and psychological factors. Past research on several of
the factors identified in this review has shown that many do play a role in aspects of
physical functioning including gait speed. While reviews on the effects of other specific
factors such as cognitive functioning and dual-tasking have provided evidence that these
individual traits significantly influence gait speed, they only provide information about a
limited number of contributors to the causal pie for gait speed decline. Thus, the current
review is a step towards identifying a more complete series of potential risk factors that
influence the likelihood of gait speed decline as well as some factors unlikely to be
fruitful avenues for subsequent research.
This systematic review is not without limitations. First, it includes many cross-sectional
studies which hinders the ability to draw conclusions about the causal relationship
between the identified risk factors and gait speed impairment. As mentioned above, there
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is noticeable heterogeneity in the classification of slow gait or meaningful speed decline
across the studies, inconsistency in walking test distance, inconsistency in the types of
covariates adjusted for, and differences in the operational definitions and comparisonreference categories of these risk factors. While the inclusion of populations of older
adults residing in community settings was not limited by geographic location,
generalizing the findings of this review to older community-dwelling adults in any
country or geographic area is cautioned strongly not only due to possible differences in
demographic, socioeconomic, lifestyle, and clinical characteristics between populations
in developed and developing countries, but also due to the other issues listed above.
We provide systematic evidence to suggest that the risk of experiencing slow gait speed
or clinically meaningful gait speed decline can be influenced by a variety of potentially
modifiable factors such as physical activity, education, body mass index, pain, and
depression/depressive symptoms. With a better understanding of the multifactorial causes
of gait speed impairments, enhancement of current methods to diagnose older adults at
risk for slow gait is possible, and individual clinical and lifestyle intervention strategies
can be tailored to target factors that contribute the highest amount of risk. Public health
interventions that target older populations can also be refined to provide education about
the risk factors associated with gait speed decline and how preventing slow gait can, in
turn, reduce the risk of associated illness and injury in the future. Due to the
inconsistencies and limitations that still exist in the current evidence base, additional
longitudinal studies on aging populations are needed to explore the causal relationships
between the factors that have been suggested to be associated with slow gait or
meaningful gait speed decline. When conducting these studies, investigators should
consider the use of one “best” walking test protocol and should consider implementing
consistent cutoff values to mark the development of slow gait speed or experience of
meaningful gait speed decline. Additionally, when investigators operationalize slow gait
with sample-based distributional cutoffs, they should also conduct parallel analyses using
uniform external cutoffs (e.g. < 0.8 m/s) to increase the comparability of their analyses to
those from other studies.
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2.6 Conclusion
There are several potentially modifiable risk factors that may impact the risk of slow gait
or meaningful declines in gait speed among community-dwelling older adults. This
preliminary synthesis of sociodemographic, clinical, lifestyle, anthropometric, serum,
cognitive, and dietary risk factors presents avenues for further investigations of the
complex etiology of this mobility impairment. Rather than using only statistical
significance as the basis for future research, investigators should ensure their studies have
adequate power to detect clinically meaningful associations between slow gait and the
factors of interest. The methods used to operationalize slow gait and meaningful gait
speed decline should also be considered when interpreting and comparing results among
studies as they can contribute to heterogeneity in risk factor effects.
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Chapter 3

3 Detailed Methods for Chapters 4 and 5
3.1 Overview
This chapter provides information on the Canadian Longitudinal Study on Aging (CLSA)
from which data was obtained for the analyses presented in Chapters 4 and 5. Section 3.2
provides a description of the data source, including the sampling design and data
collection and management procedures. The measurement instruments used to collect
data on the main outcome and all independent variables are detailed in Section 3.3.
Information on the statistical analyses performed and other considerations in subsequent
chapters are listed in Section 3.4.

3.2 Data Source
The data used in this thesis came from the CLSA. Specifically, Chapters 4 and 5 involved
analyses of baseline data from the CLSA Comprehensive cohort collected from May
2012 to May 2015. The CLSA is a national longitudinal study aimed at evaluating health
trajectories across the adult lifespan and characterizing determinants of aging processes
in a representative sample of community-dwelling Canadian adults.1 The CLSA was
developed by the Institute of Aging in partnership with Statistics Canada, the
Government of Canada, the Public Health Agency of Canada, provincial ministries, and
multiple university research institutions.

3.2.1 Sampling Design and Recruitment
Community-dwelling Canadian adults who were aged 45 to 85 years at the time of
baseline data collection were the target population for the CLSA. In total, the CLSA
recruited approximately 50,000 subjects at baseline, with about 20,000 of those
individuals in the Tracking cohort who provided information via computer-assisted
telephone interviews, and another 30,000 in the Comprehensive cohort who underwent
face-to-face interviews, performed physical assessments, and provided biological samples
during assessments in-home or at the data collection site nearest to them.2 Individuals
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were excluded from the CLSA if they were living in one of the territories, certain remote
areas, or in a First Nations reserve or settlement, or if they were full time members of the
Canadian Armed Forces, institutionalized, unable to communicate in English or French,
or were cognitively impaired.2 The studies in this thesis focused solely on data from the
Comprehensive cohort as only the people in this cohort underwent gait speed
assessments.
Several sampling frames were used in the creation of the CLSA Comprehensive cohort to
ensure it was nationally representative, including provincial healthcare registration
databases and random digit dialing.2,3 Due to the requirement of attending in-person
assessments, only individuals living within 25 to 50 kilometers of the data collection sites
were recruited for the Comprehensive cohort. Across 7 provinces, there was a total of 11
data collection sites to represent the Pacific Coast, the Prairies, Central Canada, and the
Atlantic Region.2
Sample size targets in each province were as follows: n = 3,000 for Alberta, Manitoba,
Newfoundland and Labrador, and n = 6,000 for British Columbia, Ontario, and Quebec.3
Strata were created within each province based on biological sex and 10-year age group
(i.e. 45-54, 55-64, 65-74, 75-85) resulting in a total of 56 strata for the Comprehensive
cohort.3 These strata were further crossed with education level (i.e. low education vs. not
low education). To obtain samples from provincial health registries, provincial
government departments were asked to mail CLSA information packages with returnable
consent forms to eligible individuals within that respective province. Provinces that
granted access to their registries for sampling were Ontario, Manitoba, British Columbia,
Newfoundland and Labrador, and Nova Scotia. Information packages were first mailed to
a stratified random sample of all eligible individuals in the province, and then to specific
low-education areas that were underrepresented in the initial round of sampling.3 To meet
the sampling quotas unfulfilled from sampling the provincial health registries alone,
additional participants were recruited through random digit dialing, whereby a random
sample of landline phone numbers of residences within 25 to 50 kilometers of each data
collection site was generated.3 Calls were made to these households to determine if any
people living there met the inclusion criteria and if they were willing to participate in the
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study. Finally, adults in the Quebec NuAge cohort study aged 75 to 85 years were
contacted to obtain permission to use their data in the CLSA. NuAge participants who
consented to providing their information were included in the Comprehensive cohort as
random digit dialing participants.3

3.2.2 Data Collection Procedures
After agreeing to participate in the CLSA Comprehensive cohort, eligible individuals
underwent in-home baseline interviews administered by trained CLSA staff. During these
interviews,

participants

Comprehensive

provided

Main-wave

informed

In-home

consent

Questionnaire

and
to

then

gather

completed

the

information

on

sociodemographic characteristics, health status, lifestyle behaviours, and cognitive
function.2 Following completion of an in-home interview, participants underwent further
assessment at the data collection site nearest to them to measure their physical function
and complete a Comprehensive Main-wave Disease Symptoms Questionnaire and
neuropsychological battery.2 Blood and urine samples were also obtained from
participants who consented to providing biological specimens.
To date, the CLSA employs both a manual and electronic data storage system with
safeguards to ensure the maintenance of security and privacy of all data collected.2 Data
collected from all sites across Canada are sent to a centralized server at the CLSA
National Coordinating Centre at McMaster University. Using the Opal program, data
cleaning and management is performed by staff at the Statistical Analysis Center.
Applications for access to CLSA data are reviewed by the Data and Sample Access
Committee, and once access is granted, Opal is used to send de-identified data to
researchers.

3.3 Measurement Instruments
In the following section, details on the measurement instruments used to collect data on
the variables of interest for the analyses in subsequent chapters are given.
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3.3.1 Main Outcome
Gait speed is the main outcome variable in both Chapters 4 and 5 and was used as a
continuous variable. A four-meter walk test with a static start was used to measure usual
gait speed.4 Participants were asked to stand with their toes behind a line marked on the
floor and were told to walk straight at their usual pace until they walked a few steps past
another line 4-meters away. Timing began immediately after the assessor said, “Ready,
set, go,” and stopped once the participant completely crossed the 4-meter finish line.
Participants could use assistive devices such as canes and walkers to complete the test if
needed. Time to complete the walk once was recorded in seconds using a stopwatch and
was converted into meters per second (m/s).

3.3.2 Independent Variables
Descriptions of the independent variables used in Chapters 4 and 5 are provided below.
To note, responses for categorical and binary variables recorded as ‘Don’t Know’ or
‘Refused’ in the CLSA dataset were treated as missing values.

3.3.2.1 Sociodemographic Characteristics
Age, Sex & Province: CLSA leaders recommend that age, sex, and province be included
as the minimum set of covariates for adjustment in analyses using this data.3 Participants’
ages were determined by asking for their date of birth and their sex was coded as either
‘female’ or ‘male’. The CLSA Comprehensive cohort had representation from seven
provinces: Alberta, British Columbia, Manitoba, Newfoundland and Labrador, Nova
Scotia, Ontario, and Quebec. Sex and age categorized into four 10-year groups (45-54,
55-64, 65-74, 75+) were used in Chapter 4 while sex, age (continuous), and province
were included in Chapter 5. Both age and sex have been associated with variations and
declines in gait speed over the adult lifespan. The association between older age and
slower gait speed has been well documented.5 This age-related decline in mobility is
broadly understood to be the result of physiological, compositional, and structural
changes that occur within the body which influence systems that are essential for physical
function (e.g. musculoskeletal system).6,7 Studies have also observed that men tend to
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walk faster than women on average, however anthropometric characteristics, such as leg
length, likely account for these apparent sex differences in gait speed.8
Race: To capture racial diversity, participants were asked if they identified with the
following individual groups: White, Chinese, South Asian, Black, Filipino, Latin
American, Southeast Asian, Arab, West Asian, Japanese, Korean, North American
Indian, Inuit, Métis, or Other. Since most Canadians identify as white,9 the white race
variable coded as ‘white’ and ‘not white’ was used in Chapters 4 and 5. Current evidence
suggests that the burden of physical disability is unequal across different racial
communities. Namely, racial minorities often face a greater risk of mobility and other
functional impairments, likely as a result of the effects of socioeconomic disparities such
as poverty, low education, and restricted access to healthcare.10,11
Level of Education: The highest level of education attained was recorded using four
levels coded as (1) ‘Less than secondary school graduation’, (2) ‘Secondary school
graduation, no post-secondary education’, (3) ‘Some post-secondary education’, and (4)
‘Post-secondary degree/diploma’. This categorical variable was used in Chapters 4 and 5.
Research has demonstrated that education level is significantly associated with healthrelated outcomes and physical functioning across the adult lifespan. Individuals who are
less educated are more likely to engage in unhealthy behaviours and often have poorer
health which increases the risk of functional declines in older age.12 Those with fewer
years of education may also lack adequate health literacy skills to navigate healthcare
services and proactively manage their health when issues such as mobility difficulties
arise.13

3.3.2.2 Anthropometric & Clinical Characteristics
Height & Weight: Participants’ standing heights without shoes were measured using a
Seca 213 stadiometer and their weights were measured using the 140-10 Healthweigh
digital physician scale. Height was included in both Chapter 4 and 5 while weight was
included in Chapter 5. Both continuous variables were included as covariates to account
for their potential influence on gait speed. Namely, taller height may lead to faster
walking speeds and heavier weight may contribute to slower walking speeds.14,15
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Grip Strength: Grip strength was measured using a Tracker Freedom® Wireless Grip
Dynamometer. While sitting in a chair with their feet flat on the floor and arms
unsupported, participants held the dynamometer in their dominant hand and kept their
elbow bent at a 90-degree angle.16 They were then instructed to squeeze the dynamometer
as hard as possible. This was performed three times and their average grip strength in
kilograms was calculated. Average grip strength was used as a continuous variable in
Chapter 5. Grip strength is frequently used as a measure of overall muscle strength in
clinical settings, with lower grip strength values indicating potential muscle weakness.17
Muscle weakening is a common issue in older adulthood that, if not managed effectively,
can increase the risk of functional declines and mobility impairments.18
Chronic Pain: Experience of chronic pain was assessed by asking participants, “Are you
usually free of pain or discomfort?” Responses were recorded as either ‘Yes’ or ‘No’,
with ‘No’ indicating presence of chronic pain. This binary variable was used in Chapter
5. Pain is a complex phenomenon that influences multiple aspects of everyday function;
for example, cognition, social involvement, emotional wellbeing, and physical ability.19
In older adults especially, pain and its associated morbidity are prevalent and can
contribute to and worsen mobility impairments, which has been demonstrated in previous
investigations.20,21
Incontinence: Experience of any kind of incontinence was assessed by asking, “Do you
ever have trouble getting to the bathroom in time?” Responses were recorded as either
‘Yes’ or ‘No’, with ‘Yes’ indicating experience of incontinence. This binary variable was
used in Chapter 5. Incontinence is a geriatric syndrome that can have debilitating effects
on functional ability and independence. Links between incontinence and slower walking
have previously been demonstrated in older adults, with the potential for a bidirectional
relationship proposed.22,23
Depressive Symptoms: Depressive symptoms were assessed using the Center for
Epidemiologic Studies Short Depression Scale (CESD-10). This screening tool contained
ten questions related to the frequency of feeling depressed and lonely, the ability to ‘get
going’, and restless sleep, to which participants could select one of four responses (i.e. all
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of the time, occasionally, some of the time, rarely or never).2 Overall scores ranging from
0 to 30 were derived from the ten items in the CESD-10 questionnaire to create a count
variable and this was used in Chapter 5. Depression is a prevalent neuropsychiatric
disorder that has been linked to a greater risk of multimorbidity, disability, and poor
health behaviours.24 Investigations of the causes of depression have highlighted that this
condition likely shares similar pathophysiological pathways with impairments related to
mobility and fraily.25 As a result, studies have found depression or higher number of
depressive symptoms to increase the risk of slower gait speed and vice versa.26,27
Sleep Disturbance: To operationalize sleep disturbance in Chapter 5, a variable
measuring the frequency of waking up and having trouble falling asleep was chosen.
Participants were asked, “Over the last month, how often did you wake in the middle of
the night or too early in the morning and found it difficult to fall asleep again?” Their
responses were categorized into one of five options: (1) ‘Never’, (2) ‘< Once per week’,
(3) ‘Once or Twice per week’, (4) ‘3-5 times per week’, and (5) ‘6-7 times per week’.
The ‘Never’ and ‘< Once per week’ categories were combined, resulting in four
categories overall. Although research on the association between gait speed and sleep
quality is limited, some studies have found that poorer sleep, operationalized using a
variety of methods, may be associated worse physical function including slower gait
speed.28–30 Conclusions, however, are still mixed lending to the need for further
investigation on the potential of sleep issues to influence gait.
Serum Biomarkers: Non-fasting blood samples were taken from consenting participants
during their data collection site visits. Basic analyses of the samples were performed at
the data collection sites while more complex analyses were performed at other sites
including Biorepository and Bioanalysis Centre at McMaster University and the Genetic
and Epigenetic Centre in Vancouver.2 The following serum components were used as
continuous variables in Chapter 5: vitamin D in mmol/L, high sensitivity C-reactive
protein (hsCRP) in mg/L, and high-density lipoprotein cholesterol (HDL) in mmol/L. The
values for vitamin D and hsCRP were transformed using the square-root and natural
logarithm transformations respectively to reduce skewness. Current literature suggests
that impairments in mobility may be associated with Vitamin D deficiencies,31–33 chronic
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inflammation indicated by elevated hsCRP levels,34 and lower HDL cholesterol levels
which are linked to an increased risk of multiple chronic diseases.35,36

3.3.2.3 Cognitive Function
Multiple domains of cognition play a crucial role in the production of gait. As such, the
incidence and progression of cognitive deficits often leads to gait abnormalities including
slower gait speed.37 Investigations of the role of executive functioning in gait
performance have shown that it significantly influences the control and execution of
gaiting behaviours as individuals navigate through their environment, and that impaired
executive functioning can lead to gait speed declines.37,38 In addition to this, performance
in other domains such as memory and verbal fluency have also been correlated with gait
speed,39–41 demonstrating the complex relationship between cognition and mobility.
Executive Function: The Mental Alternation Test (MAT) and the Stroop Test were used
as measures of executive function in Chapter 5.2 For the MAT, participants were asked to
alternate as many numbers and letters as they could out loud (i.e. 1-A, 2-B, 3-C, etc.) in
30 seconds. The number of correct alternations, which could range from 0 to 51, was
used as a count variable. The Stroop Test involved three trials. First, as a baseline
measure, participants were asked to say the colour of solid circles. In the next trial,
participants were asked to say the ink colour of printed words. Finally, the third trial
required participants to say the ink colour of printed colour names. The times to complete
each trial were recorded in seconds. For the Chapter 5 analysis, a Stroop Interference
variable was created by subtracting participants’ Trial 1 (least difficult) time from their
Trial 3 (most difficult) time.42 Extreme outliers ± 3 standard deviations were excluded
from the analyses (i.e. three individuals excluded with the highest scores deemed
abnormal).
Memory & Verbal Fluency: Memory was assessed using the Rey Auditory Verbal
Learning Test (RAVLT).2 For this test, participants were read a list of 15 words. Trial
one (REY I) involved immediate recall where participants were asked to recall as many
words as possible in 90 seconds immediately after the list was read to them. The second
trial of the test (REY II) involved delayed recall where participants were asked to recall
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words from the same list in 90 seconds after a 30-minute delay. Verbal fluency was
assessed using the Animal Fluency Test (AFT).2 For this test, participants were asked to
name as many different animals as possible in 60 seconds. The REY I, REY II, and AFT
scores were used as count variables in Chapter 5.

3.3.2.4 Lifestyle Behaviours
Smoking Status: Participants were asked if they were either (1) current smokers, (2)
non-smokers who have never smoked, or (3) former smokers who currently do not smoke
but have in the past. Smoking is a known risk factor for several key cardiovascular
conditions that can influence physical health and is associated with unhealthy behaviours
that can also contribute to the progression of functional declines.43,44
Alcohol Consumption: Participants’ alcohol consumption was assessed by asking if they
were either (1) regular drinkers (i.e. at least one drink per month), (2) occasional drinkers,
or (3) non-drinkers (i.e. no alcohol consumed in the last 12 months). Prior research has
suggested that alcohol consumption may impart health benefits in older age. For example,
one study demonstrated that consumption of moderate amounts of alcohol may be linked
to better physical performance, including faster gait speed, as compared to those who
drink excessively or not at all.45
Physical Activity: Participants’ level of physical activity was measured using the
Physical Activity Scale for the Elderly (PASE) questionnaire.2 Using a set of
standardized questions, participants were asked about their engagement in walking, sports
and recreational activities, household activities, and work/volunteer activities over the
past 7 days. The frequency and time spent participating in each activity was recorded to
generate a weighted score for each item. Scores for each questionnaire item were
summed to produce an overall score, which was used as a continuous variable in Chapter
5. Physical activity is important throughout life to maintain health and mobility and is
especially beneficial in older age to counteract age-related declines. For example,
previous studies have shown that older adults who are physically active are more likely to
have greater muscle strength and are at a lower risk of physical impairments .46
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3.3.2.5 Chronic Conditions
Chronic conditions can have complex negative effects on health and mobility, especially
in older adulthood.47–49 Diagnosis of chronic conditions was assessed in the CLSA
through self-report by asking participants, “Has your doctor ever told you that you
have…” to which they answered ‘Yes’ or ‘No’ to each item. These binary variables were
used in Chapter 5 either individually or were combined to create new binary composite
variables and were classified as either non-modifiable or potentially modifiable.
Non-Modifiable Chronic Conditions: Three non-modifiable conditions were included
in the analyses: (1) Neurodegenerative disease (Dementia/Alzheimer’s disease,
Parkinson’s disease/ Parkinsonism, and/or multiple sclerosis), (2) memory problem, and
(3) macular degeneration.
Potentially Modifiable Chronic Conditions: Nine potentially modifiable conditions
were included in the analyses: (1) cardiovascular condition (heart disease, peripheral
vascular disease, angina, and/or heart attack), (2) stroke (stroke and/or transient ischemic
attack), (3) diabetes, (4) hypertension, (5) cancer, (6) osteoarthritis (knee and/or hip
osteoarthritis), (7) sensory impairment (fair/poor self-rated hearing and/or fair/poor selfrated vision), (8) neuropsychiatric condition (anxiety disorder, mood disorder, epilepsy,
and/or migraine headaches), and (9) respiratory condition (asthma and/or emphysema/
chronic bronchitis/ COPD/ other chronic lung issues).

3.4 Statistical Analysis
Methods for application of the complex survey analysis in Chapters 4 and 5 are described
in section 3.4.1. Analyses for Chapters 4 and 5 are detailed in sections 3.4.2 and 3.4.3
respectively. Other considerations regarding missing data for the analyses in Chapter 5
are explained in subsequent sections.

3.4.1 Statistical Software and Complex Survey Analysis
The analyses in Chapters 4 and 5 were performed using IBM SPSS Statistics for
Windows Version 25.0 and SAS Version 9.4. To account for the sampling procedures
used to create the CLSA cohort, complex survey analysis was performed.3 In general,
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(trimmed) inflation weights were applied in descriptive analyses and analytic weights
rescaled to sum the actual sample size of the Comprehensive cohort were applied in
regression analyses. Geographic strata specific to the Comprehensive cohort and cluster,
given as each participant’s identification number, were specified in the software as well.

3.4.2 Preliminary Descriptive Analyses
Prior to conducting the analyses in Chapters 4 and 5, descriptive statistics were generated
for the overall CLSA Comprehensive cohort baseline sample (n=30,097) using the mean
± standard error (SE) or median and interquartile range for continuous variables and
frequency and percentage for categorical variables. These descriptive statistics, along
with the proportion of missing data for each variable, are presented in Appendix D (Table
D-1). The distributions of each continuous variable were visually inspected using
histograms to assess normality. Multicollinearity was assessed with a correlation matrix,
with a correlation coefficient of 0.8 used as the cutoff to indicate collinearity. The
linearity of the relationships between gait speed and the independent variables was
further inspected using scatterplots. Continuous variables were transformed if their values
were greatly skewed (Chapter 5: variables transformed were vitamin D and hsCRP due to
large positive skew), and extreme outliers were excluded if values were 3 or more
standard deviations from the mean (Chapter 5: outliers excluded in Stroop interference
variable).

3.4.3 Analyses for Chapter 4
A total of 30,097 participants in the CLSA Comprehensive cohort completed baseline
assessments. Participants were included in the Chapter 4 analyses if they had data on age,
sex, gait speed, and height. After listwise exclusion, 29,700 (98.7%) of participants had
complete data on the variables of interest. Comparisons of the characteristics of
individuals included in the analysis with those who were excluded (n=397) were
conducted using two-tailed t-tests and chi-square tests for continuous and categorical
variables respectively. The distribution of gait speed for the analytic sample was also
visually inspected using a histogram.
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The primary objective of Chapter 4 was to generate normative statistics (i.e. population
norms) for gait speed in the analytic sample by sex and age. Eight strata were created by
crossing sex (male, female) with 10-year age group (45-54, 55-64, 65-74, 75+). The mean
gait speed, standard deviation, and 95% confidence interval was tabulated for each
stratum. Since leg length can influence the pace at which individuals normally walk,50,51
gait speed values standardized by height were also tabulated by dividing gait speed by
average height in meters.
The second objective of Chapter 4 was to measure the prevalence of slow gait in each sex
and age stratum. As ‘slow gait’ can be defined in different ways (Figgins et al. 2020,
under review), three criteria were employed: 1) gait speed less than 1.0 m/s but greater
than or equal to 0.8 m/s, 2) gait speed less than 0.8 m/s but greater than or equal to 0.6
m/s, and 3) gait speed less than 0.6 m/s. These cutoffs were chosen as they have been
associated with increased risks of adverse outcomes including falls and hospitalization,
level of functional independence, and mobility in adults.52–54 A fourth gait speed category
for individuals with gait speeds greater than 1.0 m/s was also included as gait speeds
faster than 1.0 m/s are considered normal for adults.

3.4.3.1 Variance Estimation
In studies with complex sampling designs, individuals from different population
subgroups have variable probabilities of being sampled. Thus, to calculate accurate
measures of variance, departures from simple random sampling in the complex sampling
design must be accounted for.55 Current complex survey analysis programs do not
directly produce standard deviations for variables. As such, the Taylor series linearization
method was used in SAS with PROC SURVEYMEANS to estimate the standard
deviations for the gait speed estimates in each sex and age stratum while incorporating
the complex sampling design.56 Briefly, Taylor linearization is a method used to obtain
finite population variance estimators for parameters in samples with complex survey
designs.55 It involves using the sample mean of a variable of interest and the sum of the
̂ ) and population mean of
sampling weights to first estimate the total population size (𝑁
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the variable (𝑦̂). Using these, a variable (z) can be generated with a value for each
observation in the sample equal to:
𝑧𝑘 =

1
2
(𝑦𝑘 − 𝑦̂)
̂−1
𝑁

𝑘 = 1, … , 𝑛

The weighted total of this new variable is then estimated, and the square root is taken to
obtain the finite population standard deviation for the variable of interest.56

3.4.4 Analyses for Chapter 5
The analyses in Chapter 5 also used baseline data from the CLSA Comprehensive cohort.
Participants were included if they had complete data on gait speed as well as the
following independent variables: age, sex, province, education level, race, height, weight,
all twelve chronic condition variables, all five cognitive score variables, vitamin D,
hsCRP, HDL, CESD-10 score, grip strength, pain, incontinence, sleep disturbance, PASE
score, smoking status, and alcohol consumption. Of the 30,097 participants in the CLSA
Comprehensive cohort who completed the baseline assessment, 20,201 (67.1%)
individuals had complete data for gait speed along with all other variables of interest.
Descriptive statistics for the analytic sample (n=20,201) were generated, with mean and
standard error reported for continuous variables and frequency and percent reported for
categorical variables. T-tests and chi-square tests were conducted to determine if any
characteristics of the sample differed significantly from those excluded (n=9,896) as a
result of selection bias.
The first objective was to assess the bivariate associations between gait speed and the
independent factors that are non-modifiable and potentially modifiable. This was done
using the Complex Samples General Linear Model (CSGLM) procedure in SPSS (from
menu: Analyze > Complex Samples > General Linear Model). The second objective was
to construct a regression model with the non-modifiable and potentially modifiable
factors to measure the amount of variation in gait speed explained by these factors and to
further investigate the associations of the potentially modifiable factors with gait speed.
Hierarchical multivariable linear regression modelling was performed using CSGLM in
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SPSS as well with gait speed as the continuous dependent variable. Hierarchical
multivariable linear regression modelling is used to examine the amount of variance in a
dependent variable that is explained by multiple predictors that are entered sequentially in
pre-specified sets. The independent variables for this analysis were grouped prior to
running the regression resulting in five hierarchical models as listed in Table 3-1. The
rationale for the order of the variable sets was to adjust the model first for fundamental
sociodemographic and design-based variables, followed by non-modifiable factors, then
by potentially modifiable cognitive factors, then modifiable chronic diseases, and finally
by clinical and lifestyle factors. Regression coefficients with 95% confidence intervals
and statistical significance were reported for each model. The R2 value for each model
was also given to show the amount of variance in gait speed that was explained by the
addition of each set of variables.
Table 3-1. Hierarchical models.
Model 1

Sociodemographic factors (age, sex, province, race, education)

Model 2

Model 1 + Non-Modifiable Chronic Conditions (Neurodegenerative disease, memory
problem, macular degeneration) + Anthropometric factors (height, weight)

Model 3

Model 2 + Cognition (REY I, REY II, AFT, MAT, Stroop Interference)

Model 4

Model 3 + Modifiable Chronic Conditions (cardiovascular condition, stroke,
diabetes, hypertension, cancer, osteoarthritis, sensory impairment, neuropsychiatric
condition, respiratory condition)

Model 5

Model 4 + Other Modifiable Clinical/Lifestyle Factors (vitamin D, hsCRP, HDL,
depressive symptoms (CESD-10), grip strength, chronic pain, incontinence, sleep
disturbance, physical activity (PASE), smoking status, alcohol consumption)

3.4.4.1 Missing Data
Patterns among missing values for all variables of interest were examined prior to
conducting the analyses. When selecting only cases with complete data for all variables,
approximately 67% of individuals had valid responses. Vitamin D, hsCRP, and HDL had
the largest percentages of missing cases (10.3% each). The data were assumed to be
missing at random (MAR), meaning that other variables in the dataset may predict the
missingness in certain variables but the variables themselves do not predict their own
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missingness.57 Listwise deletion of cases was used first to manage missing values across
all the variables of interest which resulted in a sample size of 20,201.
Missing value analysis was also performed on the sets of chronic condition variables used
to create each composite variable to determine if it would be appropriate to exclude cases
with missing responses to any of the individual variables being considered in a set. Both
the proportion of missingness as well as patterns of missingness were evaluated. Overall,
the proportion of cases excluded for having any missing values was low, with 0.4%,
2.1%, 0.9%, 2.0%, 0.7%, 0.7%, and 0.1% of cases excluded for the neurodegenerative
disease, cardiovascular condition, stroke, osteoarthritis, neuropsychiatric condition,
respiratory condition, and sensory impairment composite variables respectively.
Additionally, no appreciable associations were seen between missing responses and age,
sex, and other variables in each composite set. This justified the use of cases only with
valid ‘Yes’ or ‘No’ responses to the entire set of individual conditions being considered
for each composite variable.57
Since the data were assumed to be MAR but not missing completely at random (MCAR),
analyzing only complete cases may introduce bias in the estimates.58 As such, multiple
imputation of missing values was performed, and the hierarchical regression analysis was
conducted again as a sensitivity analysis to determine if the missingness introduced any
bias into the results. The fully conditional specification (FCS) method for arbitrary
missing data patterns was chosen for multiple imputation. This method allows for
imputation of both continuous and categorical variables as it uses a separate conditional
distribution for each variable in the model.58 Binary and categorical variables were
imputed using the discriminant function and continuous variables were imputed using
predictive mean matching.59 To account for the complex survey design, the sampling
weight variable was also included as a covariate in the model.60 Following guidelines
proposed by White et al. that the number of imputed data sets should be equal to the
proportion of missing cases,59 30 imputed datasets were created. Imputation diagnostics
were then run in SAS by inspecting trace plots and comparing summary statistics for the
imputed and original data (Appendix D, Table D-1).58 SPSS Version 25.0 software does
not currently include tools to analyze complex survey data that has had missing data
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imputed through multiple imputation. Thus, to perform a sensitivity analysis with missing
values imputed, the CLSA dataset was imported into SAS Version 9.4 to run multiple
imputation and perform the regression analysis using the PROC SURVEYREG and
PROC MIANALYZE functions.
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Chapter 4

4 Normative Values of Gait Speed among Middle and OlderAged Adults: An Analysis of Data from the Canadian
Longitudinal Study on Aging
4.1 Introduction
Gait speed is a parameter of mobility that is the product of multiple biomechanical,
physiological, and sensory processes.1–5 Due to their complex interactions, impairments
in these underlying processes can disrupt the production and maintenance of normal gait
speed, especially in older adults. Given that gait speed can be measured easily and
objectively during clinical assessments, this behaviour is commonly used as an indicator
of health quality and functional independence.6 It is also used to predict older individuals’
risks of experiencing adverse outcomes including falls, hospitalizations, and mortality.7,8
Many methods currently exist to measure gait speed, however shorter distance timed
walk tests between 4 and 10 meters in length are most frequently employed.9 While timed
walk tests are widely implemented in clinical settings, the results of these tests are not
easily interpretable without normative values for reference. Population norms have long
been used in clinical areas like pediatrics to identify children whose height or weight is
substantially below average for their age (e.g. below the fifth or tenth percentile). Norms
are based on large representative samples and can be reported separately by sex or other
sociodemographic variables. In the context of gait speed, clinical assessors can use
norms, which are commonly separated by covariates such as sex and height, to determine
if an individual patient is performing within the range of function that is expected based
on their demographics. Additionally, an individual’s gait speed can be expressed in
percentile terms both at one point in time as well as to measure relative change over time.
This comparative information can be used as a screening tool to further identify those
who may have underlying impairments that have yet to be diagnosed or who are at an
increased risk for developing additional health issues in the future.10
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Normative statistics such as percentile equivalents reflect the composition of the
population from which the sample was drawn. Several studies have previously generated
normative values for gait speed in older adults from various populations.11–14 While
informative, there is noticeable heterogeneity in the values obtained, and due to the
variability in the source and size of the samples used, these values may not be truly
representative of the gait speed norms of other specific populations with different
characteristics. To address these gaps, the present study analyzed baseline data from the
Canadian Longitudinal Study on Aging (CLSA), a large nationally representative sample
of Canadians aged 45-85 years of age, with the following three objectives:
i)

To estimate the normative values of gait speed for Canadian men and
women in four age groups (45-54, 55-64, 65-74, 75+ years)

ii)

To estimate the prevalence of ‘slow gait’ using three common cut-point
ranges: ≥ 0.80 to < 1.00 m/s, ≥ 0.60 to < 0.80 m/s, and < 0.60 m/s

iii)

To demonstrate the transformation of an individual’s gait speed into a
population percentile

4.2 Methods
4.2.1 Source Population
This study involved cross-sectional analysis of baseline data from the CLSA
Comprehensive cohort collected between May 2012 and May 2015. The CLSA is a
national longitudinal study aimed at evaluating health trajectories across the adult
lifespan and characterizing determinants of aging processes in a representative sample of
community-dwelling Canadians adults.15 In total, the CLSA recruited approximately
50,000 subjects aged 45 to 85 years at baseline, with about 20,000 of those individuals in
the Tracking cohort who provided information via computer-assisted telephone
interviews, and another 30,000 in the Comprehensive cohort who underwent face-to-face
interviews, performed physical assessments, and provided biological samples during
assessments in-home or at the data collection site nearest to them.16 The present study
focused solely on data from participants in the Comprehensive cohort as only the people
in this cohort underwent gait speed assessments.
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Several sampling frames were used in the creation of the CLSA Comprehensive cohort to
ensure it was nationally representative including provincial healthcare registration
databases and random digit dialing.16,17 Strata were created within each province based
on sex and age group (45-54, 55-64, 65-74, and 75-85) resulting in a total of 56 strata for
the Comprehensive cohort.17 These strata were further crossed with education level.
Individuals were excluded if they were living in one of the territories, certain remote
areas, or in a First Nations reserve or settlement, or if they were full time members of the
Canadian Armed Forces, institutionalized, unable to communicate in English or French,
or were cognitively impaired.16 Due to the requirement of attending in-person
assessments, only individuals who were living within 25 to 50 kilometers of the data
collection sites were recruited for the Comprehensive cohort.

4.2.2 Study Sample
Upon sampling completion, the CLSA had enrolled 30,097 individuals in the
Comprehensive cohort at baseline. For the present study, only individuals who had valid
data on age, sex, gait speed, and height were included in the analyses. Overall, 397
participants were excluded as they were missing data on the variables of interest,
resulting in a final sample size of 29,700.

4.2.3 Data Collection
Participants in the CLSA Comprehensive cohort underwent baseline interviews between
May 2012 and May 2015 both in-home and at the data collection centers. Participants’
ages were determined by asking for their date of birth and their sex was coded as either
‘female’ or ‘male’. The standing height of participants without shoes was measured using
a Seca 213 stadiometer and recorded in meters.16
A four-meter walk test with a static start was used to measure usual gait speed.18
Participants were asked to stand with their toes behind a line marked on the floor and
were told to walk straight at their usual pace until they walked a few steps past another
line 4-meters away. Timing began immediately after the assessor said, “Ready, set, go,”
and was stopped once the participant completely crossed the 4-meter finish line.
Participants could use assistive devices such as canes and walkers to complete the test if
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needed. Time to complete the walk once was recorded in seconds using a stopwatch and
was converted into meters per second (m/s).

4.2.4 Statistical Analysis
Comparisons of the characteristics of the 29,700 subjects included in the analysis with the
397 individuals who were excluded due to missing data were conducted using two-tailed
t-tests and chi-square tests for continuous and categorical variables respectively. The
distribution of 4-meter usual gait speed for the entire analytic sample was visually
inspected using a histogram.
To generate normative statistics on 4-meter usual gait speed, strata were formed in the
analytic sample by creating four 10-year age groups (45-54, 55-64, 65-74, 75+). The
mean gait speed, standard deviation, and 95% confidence interval were tabulated for
males and females in each of the four age groups. Since leg length can influence the pace
at which individuals normally walk, gait speed values standardized by height were also
tabulated by dividing gait speed by average height in meters.14,19,20 The mean heightstandardized usual gait speed, standard deviation, and 95% confidence interval were
tabulated for each stratum as well.
Prevalence of slow gait was reported as a count and percentage. As ‘slow gait’ can be
defined in different ways, the following three criteria were employed to generate
prevalence values: 1) gait speed less than 1.00 m/s but greater than or equal to 0.80 m/s,
2) gait speed less than 0.80 m/s but greater than or equal to 0.60 m/s, and 3) gait speed
less than 0.60 m/s. These cutoffs were chosen as they have been associated with
increased risks of adverse outcomes including falls and hospitalization, varying levels of
functional independence, and mobility declines in adults.6,7,21,22 A fourth gait speed
category for individuals with gait speeds equal to or greater than 1.00 m/s was also
included as gait speeds at or above this cutoff are generally considered normal for adults.
Analyses were performed using SAS Version 9.4 and Excel Version 16.16.8. Since the
CLSA is a complex sample survey, sampling weights were used in all the analyses to
obtain results that are representative of the Canadian population as per CLSA

63

guidelines.17 Taylor series linearization method was used to estimate the complex sample
standard deviations as this measure is not automatically produced by complex survey
software.23

4.3 Results
Of the 30,097 individuals in the CLSA Comprehensive cohort who completed a baseline
assessment, 29,700 (98.7%) had complete data for the variables of interest. Compared to
those who were included in the analytic sample, individuals who were excluded tended to
be older and had less education (Table 4-1).
Table 4-1. Characteristics of included and excluded groups.
Variable

Analytic Sample with
Complete Data
(n=29,700)
59.44 ± 0.07

Excluded Group
with Missing Data
(n=397)
63.32 ± 0.70

Age, mean ± SEa
Sex, n (%)
Female
15116 (50.3)
204 (52.8)
Male
14584 (49.7)
193 (47.2)
Race, n (%)
White
28396 (94.7)
375 (94.3)
Non-white
1304 (5.3)
22 (5.7)
Education, n (%)
Less than secondary school graduation
1606 (4.8)
37 (8.9)
Secondary school graduation only
2792 (8.9)
46 (13.5)
Some post-secondary education
2195 (6.7)
41 (9.7)
Post-secondary degree/diploma
23050 (79.6)
272 (67.9)
a
Means, standard errors, and percentages estimated using (trimmed) inflation weights.

p

< .001
.439

.753

< .001

4.3.1 Distribution of Gait Speed in the Analytic Sample
As shown in Figure 4-1, 4-meter usual gait speed in the sample appears normally
distributed. The overall mean (SD) usual gait speed of the sample was 0.999 (0.198) m/s.
The fastest gait speed in the sample was 2.564 m/s while the slowest gait speed was 0.106
m/s.
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Figure 4-1. Distribution of usual gait speed (m/s) for the analytic sample.

4.3.2 Normative Values for Gait Speed by Sex and Age
The normative values for gait speed in each sex and age group are presented in Table 4-2.
Declining trends in gait speed norms were evident across increasing age group, with
steeper decreases noticeable among females compared to males. Mean usual gait speeds
for males and females in the 45-54 and 55-64-year age groups were similar, with values
at or above 1.00 m/s. However, for individuals in the two oldest age groups, mean gait
speeds were below 1.00 m/s, especially in the 75+ year age groups where the means for
males and females were 0.884 m/s and 0.832 m/s respectively.
As seen with unstandardized gait speed, mean height-standardized gait speed values also
appeared slower with older age among males and females. However, in contrast to males
having faster average unstandardized gait speeds, women appeared to have faster mean
height-standardized gait speeds regardless of age.

65

Table 4-2. Normative values of usual gait speed and height-standardized usual gait speed by sex and age.
Males
Variable

45-54

55-64

65-74

75+

Total

(n=3644)

(n=4706)

(n=3609)

(n=2625)

(n= 14584)

Gait Speed, mean (SD)a

1.042 (0.173)

1.023 (0.194)

0.974 (0.189)

0.884 (0.189)

1.009 (0.190)

Gait Speed, 95% CI

1.036-1.048

1.017-1.029

0.968-0.981

0.877-0.892

1.006-1.013

Height-Standardized Gait
Speed, mean (SD)b
Height-Standardized Gait
Speed, 95% CI

0.588 (0.098)

0.581 (0.110)

0.559 (0.108)

0.512 (0.110)

0.574 (0.107)

0.585-0.592

0.578-0.584

0.555-0.563

0.508-0.517

0.572-0.576

Females
Variable

45-54

55-64

65-74

75+

Total

(n=3898)

(n=5023)

(n=3634)

(n=2561)

(n=15116)

Gait Speed, mean (SD)

1.045 (0.190)

1.001 (0.195)

0.940 (0.195)

0.832 (0.187)

0.988 (0.203)

Gait Speed, 95% CI

1.039-1.051

0.995-1.007

0.933-0.947

0.825-0.841

0.985-0.992

Height-Standardized Gait
Speed, mean (SD)
Height-Standardized Gait
Speed, 95% CI

0.637 (0.115)

0.618 (0.120)

0.586 (0.121)

0.525 (0.117)

0.609 (0.123)

0.634-0.641

0.615-0.622

0.582-0.590

0.520-0.530

0.607-0.612

a

Means, standard deviations, and confidence intervals estimated using analytic sampling weights.
Height-standardized usual gait speed = gait speed (m/s)/height (m)
Notes: CI=confidence interval; SD=standard deviation
b
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4.3.3 Prevalence of Slow Gait Speed
Table 4-3 shows the prevalence of individuals within each gait speed group. The 45-54
and 55-64-year age groups had the greatest proportions of males and females with
‘normal’ gait speeds at or above 1.00 m/s. However, a shift in the distributions of
individuals across the gait speed categories was apparent within the two oldest age
groups such that a larger proportion had gait speeds that were slower than 1.00 m/s.
Notably, among men and women aged 65-74 and 75+ years, those with gait speeds ≥ 0.80
to <1.00 m/s made up the largest proportion within each stratum. Further, the proportion
of males and females within the ≥0.60 to <0.80 m/s gait speed group was nearly double
between the 55-64-year and 65-74-year groups as well as between the 65-74-year and
75+ year groups (Males: 7.9%, 13.4%, 25.1%; Females: 10.0%, 18.3%, 31.9%).
Additionally, the proportion of men and women aged 75+ years whose gait speeds were
slower than 0.60 m/s was more than three times that seen for men and women in the 6574-year age group.
Table 4-3. Prevalence of gait speeds by sex and age.
Males
Gait Speed Cut-off

45-54

55-64

65-74

75+

Total

(n=3644)

(n=4706)

(n=3609)

(n=2625)

(n= 14584)

≥1.00 m/s, n (%)a

2153 (59.1)

2463 (53.0)

1535 (43.9)

658 (24.5)

6809 (51.4)

≥ 0.80 to <1.00, n (%)

1279 (35.1)

1795 (38.0)

1477 (41.1)

1119 (45.1)

5670 (37.9)

≥0.60 to <0.80, n (%)

190 (5.2)

394 (7.9)

529 (13.4)

688 (25.1)

1801 (9.4)

< 0.60 m/s, n (%)

22 (0.5)

54 (1.0)

68 (1.5)

160 (5.3)

304 (1.3)

Females
Gait Speed Cut-off

45-54

55-64

65-74

75+

Total

(n=3898)

(n=5023)

(n=3634)

(n=2561)

(n=15116)

≥1.00 m/s, n (%)

2270 (59.6)

2403 (49.7)

1277 (36.3)

458 (17.6)

6408 (47.4)

≥ 0.80 to <1.00, n (%)

1348 (33.9)

1960 (38.8)

1539 (42.5)

1000 (40.4)

5847 (37.7)

≥0.60 to <0.80, n (%)

248 (5.7)

564 (10.0)

700 (18.3)

832 (31.9)

2344 (12.4)

< 0.60 m/s, n (%)

32 (0.7)

96 (1.5)

118 (2.9)

271 (10.1)

517 (2.5)

a

Percentages estimated using (trimmed) inflation sampling weights.
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4.3.4 Expressing Individual Gait Speed as a Percentile
An individual’s gait speed is first converted to a Z score using the Excel
STANDARDIZE function.

Then, because gait speed is approximately normally

distributed (Fig. 4-1), the Z score is expressed as a percentile using the NORM.S.DIST
function:
1. Z score for individual = STANDARDIZE (X, mean, sd)
where:
X = individual’s measured gait speed in m/s
mean = stratum-specific mean gait speed from Table 4-2
sd = stratum-specific standard deviation from Table 4-2
2. Percentile for individual = NORM.S.DIST (Z, TRUE)
where:
Z = Z score from STANDARDIZE function
TRUE = a statement to produce cumulative percentiles.
Example 1 (ignoring height): Ms. A is a 75-year-old woman with a measured gait speed
of 0.85 m/s. The STANDARDIZE (0.85, 0.832, 0.187) function in Excel yields Z =
0.35719722. The NORM.S.DIST (0.35719722, TRUE) function returns the value
0.63952792. Ms. A’s gait speed is approximately equivalent to the 64th percentile for her
age and gender group.
Example 2 (incorporating height): Ms. A is 170 cm tall. Her height-normalized gait
speed = [gait speed (m/s)/height(m)] = 0.85 / 1.7 = 0.5. The STANDARDIZE (0.5,
0.525, 0.117) function returns Z = -0.2136752. The NORM.S.DIST (-0.2136752, TRUE)
function returns the value 0.58459982. When Ms. A’s height is taken into account, her
height-adjusted gait speed is approximately equivalent to the 58th percentile for her agegender group.
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4.4 Discussion
This study provides normative values of 4-meter usual gait speed and height-standardized
usual gait speed. A description of slow gait prevalence was also tabulated. These values
were obtained using a large, nationally representative sample of community-dwelling
middle and older-aged adults living in Canada.
The usual gait speed values obtained in this analysis were comparable to but generally
slower than those for similar-aged subjects in previous reports. Specifically, the mean
usual gait speeds among the two oldest CLSA age groups (65-74 and 75+) was below
0.90 m/s. Contrarily, using a 4-meter static start walk test like that employed in the
present study, Bohannon and colleagues reported average gait speeds ranging from 0.95
m/s to 1.07 m/s for men and women aged 70-79-years and 80-85-years.24 Hollman and
colleagues also reported mean gait speeds ranging from 0.98 m/s to 1.22 m/s for men and
women aged 70 years and older using 5.6-meter electronic GAITRite walkway with
acceleration and deceleration zones.11
The discrepancies in normative values may be the result of several factors. First, other
investigations of gait speed across the adult lifespan have relied on smaller and less
representative samples of community-dwelling adults to estimate population parameters.
Researchers have noted that subjects who are healthier and better functioning may be
more likely to participate in health research.25,26 In comparison, individuals were not
specifically excluded from the CLSA cohort at baseline based on walking ability or
common health conditions but rather if they had serious impairments that would impede
them from completing any of the study assessments or if they were institutionalized.
Furthermore, adults residing in seniors’ residences where minimal care is provided were
included in the baseline sample. As a result, the CLSA baseline cohort likely contained
some individuals with mild or moderate mobility impairments or other health issues that
may have influenced their gait speed. Individuals were also not excluded from the current
analysis for having gait speeds below a certain threshold. However, only a small
proportion of individuals had gait speeds slower than 0.60 m/s and their effect on the
normative values obtained would have been negligible.
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Another potential explanation for the discrepancy in mean usual gait speeds between this
study and others reporting normative values may be the type of walk test protocol used.
CLSA participants could use assistive devices such as canes and walkers if needed to
complete the walk test. Use of assistive devices during walk tests has been associated
with slower gait speeds, which may be explained not only by the devices themselves but
also by the underlying impairments that these individuals have that necessitated them
having to use an assistive device.27 Additionally, while a 4-meter test with a static start
was used to measure gait speed in this study, other studies reporting normative gait speed
values have used both shorter and longer walking distances with either static starts or
dynamic starts that include acceleration and deceleration zones. Reviews of performance
on various walking tests have suggested that compared to longer distance tests with either
a static or dynamic start, the gait speeds obtained from short distance tests with a static
start tend to be the slowest.27–29 Although the influence of these protocol elements have
been challenged,30 they must still be considered when determining if the gait speed values
obtained using a specific type of walk test are truly representative of the population they
are seeking to describe.
As a consensus on one best definition of slow gait has not yet been reached, we
additionally reported prevalence values across ranges of gait speeds below 1.00 m/s.
Previous studies investigating slow gait in samples of older adults have used a variety of
single cut-off definitions, which has led to heterogeneous prevalence estimates.31–33 By
exploring gait speed and slowness more thoroughly across the adult lifespan using
multiple cut-off points, we gain a better picture of the individuals among which this
impairment is more common, and the demographic groups that contain individuals who
have more severely impaired gait speeds.
Finally, percentile figures express the position of an individual’s performance relative to
a reference population. The age-gender-specific height-adjusted percentile ranks
calculable from our values should provide a more accurate reflection of individuals’ gait
speed performance, for example, to determine eligibility for an exercise intervention to
improve mobility.
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Due to the cross-sectional design of this analysis, measurement of changes in gait speed
over time across the demographic strata were not possible. Additionally, since this study
sample focused only on community-dwelling Canadian residents, the normative gait
speed statistics obtained may not be generalizable to other adult populations.
Nonetheless, the normative values for usual gait speed presented have the potential to be
used as a reference to aid in the interpretation of patients’ walking test results during
clinical assessments, especially in Canadian contexts.
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Chapter 5

5 Associations between Reversible Risk Factors and Gait
Speed in Middle and Older-Aged Community-Dwelling
Adults: Results from the Canadian Longitudinal Study
on Aging
A version of this chapter has been submitted for publication.

5.1 Abstract
Importance: Gait speed is an important marker of morbidity and mortality in older
adults. Investigations of the non-modifiable and potentially modifiable correlates of gait
speed in nationally representative samples are lacking. Objective: To assess the
potentially modifiable and non-modifiable factors associated with gait speed in
community-dwelling middle and older-aged adults. Design: Cross-sectional analysis of
baseline data (May 2012 to May 2015) from the Canadian Longitudinal Study on Aging
(CLSA) Comprehensive cohort. Setting and Participants: The CLSA is a cohort study
comprising a nationally representative sample of community-dwelling Canadian adults
aged 45 to 85 years at the time of baseline assessment. Exposures: Non-modifiable
factors (i.e. socio-demographics, anthropometric factors, non-modifiable chronic
conditions) and potentially modifiable factors (i.e. potentially modifiable chronic
conditions, cognitive, clinical and lifestyle factors). Main Outcome and Measure: Usual
gait speed (m/s) measured using a 4-meter walk test. Results: Of the 30,097 participants
who completed a baseline assessment, 29,705 (98.7%) had gait speed measured. Of this,
20,201 (9971 [48.6%] female; 19479 [95.7%] white) had valid data on all study
variables. The coefficient of determination, R2, of the final hierarchical regression model
was 19.7%, with the non-modifiable and potentially modifiable factor blocks explaining
15.6% and 4.1% of gait speed variability respectively. Potentially modifiable factors
significantly associated with gait speed include cardiovascular condition (unstandardized
regression coefficient, B= -.018, 95% CI= -.026; -.010; P<.001), stroke (B= -.025, 95%
CI= -.041; -.009; P=.003), osteoarthritis (B= -.012, 95% CI= -.019; -.005; P=.001), serum
Vitamin D (B= .003; 95% CI= .002; .005; P<.001), C-Reactive protein (B= -.003; 95%
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CI= -.007; -.0002; P=.039), depressive symptoms (B= -.003, 95% CI= -.003; -.002;
P<.001), physical activity (B=.0001; 95% CI= .00005; .0001; P<.001), grip strength
(B=.003; 95% CI= .002; .003; P<.001), smoking (B= -.027; 95% CI= -.038; -.017;
P<.001), chronic pain (B= -.011; 95% CI= -.017; -.005; P<.001), and trouble getting to
the bathroom on time (B= -.031; 95% CI= -.040; -.022; P<.001). Conclusions and
Relevance: The correlates of gait speed in adulthood are multifactorial, with many being
potentially modifiable through intervention, education, and lifestyle changes.

5.2 Introduction
Gait impairments are prevalent among older adults and can severely affect health and
physical function.1,2 Slow gait speed specifically is associated with severe medical
outcomes including falls and musculoskeletal injuries, multimorbidity, and mortality.3–5
Recently, it has been shown that even gait speed changes and slowing in mid-life are
associated with future adverse events and cognitive impairment.6 Due to this prognostic
value, the measurement of gait speed and its determinants in clinical settings is key to
identify and treat older individuals at risk of facing future declines.7
Maintenance of normal gait speed is complex and reflects the interplay of many factors
during adulthood that can be classified as non-modifiable and potentially modifiable. In
contrast to non-modifiable factors which are unalterable (e.g. age, sex at birth),
modifiable risk factors can potentially be altered/managed through various methods
including clinical treatment and lifestyle changes. While studies have examined a wide
range of non-modifiable and potentially modifiable factors affecting gait speed in older
adults,8–11 none have been done in large nationally representative samples including those
of middle age. To address this gap, we identified correlates of gait speed using
population-based data from the Canadian Longitudinal Study on Aging (CLSA). The
specific objectives were to assess the bivariate associations between gait speed and nonmodifiable and potentially modifiable factors and use multivariable regression to explain
maximal variability in usual gait speed. Interest was on potentially modifiable factors to
help focus intervention and education strategies in at-risk subgroups.
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5.3 Methods
5.3.1 Study Design & Source Population
This was a cross-sectional analysis of baseline data (May 2012-May 2015) from the
CLSA Comprehensive cohort. The CLSA is a Canada-wide longitudinal study of aging in
a representative sample of 50,000 community-dwelling adults aged 45 to 85 years at
recruitment.12 About 20,000 people in the Tracking cohort provided information via
computer-assisted telephone interviews, and another 30,000 in the Comprehensive cohort
underwent face-to-face interviews, performed physical assessments, and provided
biological samples in-home or at a data collection site.13
Several sampling frames were used in the creation of the CLSA Comprehensive cohort to
ensure it was nationally representative including provincial healthcare registration
databases and random digit dialing.13,14 Strata were created within each province based
on sex and age group (45-54, 55-64, 65-74, and 75-85) resulting in a total of 56 strata for
the Comprehensive cohort. These strata were further crossed with education level.
Individuals were excluded if they were living in one of the territories, certain remote
areas, or in a First Nations reserve or settlement, or if they were full time members of the
Canadian Armed Forces, institutionalized, unable to communicate in English or French,
or were cognitively impaired.13 Due to the requirement of attending in-person
assessments, only individuals living within 25 to 50 kilometers of the data collection sites
were recruited for the Comprehensive cohort.

5.3.2 Data Collection
Data collection procedures have been described elsewhere.13 Briefly, the Comprehensive
cohort baseline assessments evaluated sociodemographic characteristics, health status,
lifestyle behaviours, cognitive and physical function, and drawn blood and urine samples.
Written informed consent was obtained from CLSA participants and study protocols were
approved by the ethical review boards of participating institutions.
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5.3.2.1 Gait Speed
Usual gait speed, the primary outcome, was measured using a four-meter walk test with
static start.15 Participants stood with their toes behind a marked line and were told to walk
straight at their usual pace until they walked a few steps past another line 4-meters away.
Timing began immediately after the assessor said, “Ready, set, go,” and stopped once the
participant completely crossed the 4-meter finish line. Participants could use assistive
devices such as canes and walkers if needed. Time to complete the walk once was
recorded in seconds using a stopwatch and was converted into meters per second (m/s).

5.3.2.1 Independent Variables
Age, sex, province of residence, race, and highest level of education attained were
included as sociodemographic covariates. Standing height (meters) and weight
(kilograms) were included as anthropometric covariates.
The clinical factors included were grip strength,16,17 chronic pain evaluated with the
question, “Are you usually free of pain or discomfort?”,18 incontinence evaluated with the
question, “Do you ever have trouble getting to the bathroom in time?”,19 depressive
symptoms measured using the Center for Epidemiologic Studies Short Depression Scale
(CESD-10),20 and sleep disturbance operationalized using the question, “Over the last
month, how often did you wake in the middle of the night or too early in the morning and
found it difficult to fall asleep again?”21 The clinical serum markers included were
Vitamin D (mmol/L),22 High Sensitivity C-Reactive Protein (hsCRP; mg/L),23 and HighDensity Lipoprotein (HDL; mmol/L).24 The values for Vitamin D and hsCRP were
transformed using the square-root and natural logarithm transformations respectively
because of skewness.
Measures of cognitive function were included using the following cognitive domains:
memory (Rey Auditory Verbal Learning Test [REY I, REY II]),25 verbal fluency (Animal
Fluency Test [AFT]),26 and executive function (Mental Alternation Test [MAT]; Stroop
Test).27,28 A continuous Stroop (Interference) variable was created by subtracting
participants’ Stroop trial 1 (least difficult) time from their Stroop trial 3 (most difficult)
time, and extreme outliers ±3 standard deviations from the mean were excluded.29
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Lifestyle factors included smoking status, alcohol consumption, and physical activity
measured using the Physical Activity Scale for the Elderly (PASE).30 Self-reported nonmodifiable

chronic

conditions

included

neurodegenerative

disease

(Dementia/

Alzheimer’s disease, Parkinson’s disease, and/or Multiple Sclerosis); memory problems;
and macular degeneration. Self-reported potentially modifiable chronic conditions
included cardiovascular (heart disease, peripheral vascular disease, angina, and/or heart
attack); stroke (stroke and/or transient ischemic attack); diabetes; hypertension; cancer;
osteoarthritis (knee and/or hip osteoarthritis); sensory impairment (fair/poor self-rated
hearing and/or fair/poor self-rated vision); neuropsychiatric condition (anxiety disorder,
mood disorder, epilepsy, and/or migraine headaches); and respiratory condition (asthma
and/or emphysema/chronic bronchitis/COPD/other chronic lung issues).

5.3.3 Statistical Analysis
Descriptive statistics were generated using the mean ± standard error (SE) or median
[IQR] for continuous variables and frequency (percentage) for categorical variables. A
comparison of characteristics of the subjects included in the analysis with the group
excluded due to missing data were conducted using two-tailed t-tests and chi-square tests
for continuous and categorical variables respectively.
Bivariate linear associations between gait speed and each of the independent variables
were assessed using the Complex Samples General Linear Model (CSGLM) procedure in
SPSS (from menu: Analyze > Complex Samples > General Linear Model). Hierarchical
multivariable linear regression modelling was performed using the CSGLM procedure as
well to examine the correlates of gait speed. The independent variables of interest were
grouped a priori into five hierarchical model blocks (Table 5-1). The rationale for the
order the blocks were fitted was to adjust first for fundamental sociodemographic and
design-based variables, followed by non-modifiable factors, then by potentially
modifiable cognitive factors, then modifiable chronic diseases, and finally by modifiable
clinical and lifestyle factors. Regression coefficients, denoted by B, with 95% confidence
intervals and statistical significance were reported for each model. The coefficient of
determination, R2, for each model was examined to show the amount of variance in gait
speed that was explained by the addition of each block.
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To assess the potential for bias due to missing values, the hierarchical regression was
repeated after imputing missing data using the fully conditional specification (FCS)
method for arbitrary missing data patterns. To account for the complex survey design, the
sampling weight variable was included as a covariate in the imputation model.31
Following guidelines proposed by White et al. that the number of imputed data sets
should be equal to the proportion of missing cases,32 30 imputed datasets were created.
All main analyses were performed using IBM SPSS Statistics for Windows, Version
25.0. Due to limitations of SPSS in analyzing complex sample data sets that have had
missing values imputed through multiple imputation, SAS Version 9.4 was used to
perform multiple imputation and re-run the hierarchical regression with the imputed data.
Since the CLSA is a complex sample survey, analytic and (trimmed) inflation sampling
weights were used in the analyses to obtain results that are representative of the Canadian
population as per CLSA guidelines.14
Table 5-1. Hierarchical models used to measure correlates of gait speed.
Model 1

Sociodemographic factors (age, sex, province, race, education)

Model 2

Model 1 + Non-Modifiable Chronic Conditions (Neurodegenerative disease, memory
problem, macular degeneration) + Anthropometric factors (height, weight)

Model 3

Model 2 + Cognition (REY I, REY II, AFT, MAT, Stroop Interference)

Model 4

Model 3 + Modifiable Chronic Conditions (cardiovascular condition, stroke, diabetes,
hypertension, cancer, osteoarthritis, sensory impairment, neuropsychiatric condition,
respiratory condition)

Model 5

Model 4 + Other Modifiable Clinical/Lifestyle Factors (vitamin D, hsCRP, HDL, depressive
symptoms (CESD-10), grip strength, chronic pain, trouble getting to bathroom on time, sleep
disturbance, physical activity (PASE), smoking status, alcohol consumption)

5.4 Results
5.4.1 Sample Characteristics
Of the 30,097 participants in the Comprehensive cohort baseline, 29,705 (98.7%) had
values for gait speed. Overall, 20,201 (67.1%) participants had valid data for gait speed
and all other variables of interest. Compared to those with complete data, individuals
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excluded due to missing data (n= 9896) tended to be older, female, and non-white, with
less education, and slower gait speeds (Appendix E, Table E-1).
Table 5-2 shows the characteristics of the analytic sample. The mean age was 58.8 years
(SE=0.08) and 48.6% were female. Most participants were white (95.7%) and had a postsecondary degree or diploma (81%). The most common chronic conditions were
hypertension (30.3%), neuropsychiatric condition (29.6%), and osteoarthritis (15.7%).
The mean usual gait speed was 1.01 m/s (SE=0.002).
Table 5-2. Baseline descriptive statistics for analytic sample (n=20,201).
Variable

Population
Estimatea

Age, mean ± SE, years

58.84 ± 0.08

Height, mean ± SE, m
Weight, mean ± SE, kg
Vitamin D, mean ± SE, mmol/L
hsCRP, mean ± SE, mg/L
HDL, mean ± SE, mmol/L
Gait Speed, mean ± SE, m/s
Grip Strength, mean ± SE, kg
REY I (Immediate Recall), mean ± SE
REY II (Delayed Recall), mean ± SE
AFT, mean ± SE
MAT, mean ± SE
Stroop (Interference), mean ± SE
Depressive Symptoms (CESD-10), mean ± SE
Physical Activity (PASE), mean ± SE
Sex, No. (%)

1.69 ± 0.0009
79.57 ± 0.15
82.73 [46.3]
1.04 [1.82]
1.51 ± 0.004
1.01 ± 0.002
35.54 ± 0.11
6.11 ± 0.02
4.37 ± 0.02
20.70 ± 0.05
27.91 ± 0.08
12.79 ± 0.06
4.98 ± 0.04
154.38 ± 0.73

Female
Male
Province, No. (%)
Alberta
British Columbia
Manitoba
Newfoundland and Labrador
Nova Scotia
Ontario
Quebec
Race, No. (%)
White
Non-white
Highest Education Level, No. (%)
Less than secondary school graduation
Secondary school graduation only

9971 (48.6)
10230 (51.4)
1871 (11.5)
4237 (29.9)
2286 (8.8)
1446 (2.1)
2004 (3.4)
4279 (12.9)
4078 (31.4)
19479 (95.7)
722 (4.3)
910 (4.0)
1795 (8.6)
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Some post-secondary education
Post-secondary degree or diploma
Trouble to get to bathroom on time, No. (%)
Yes
No
Chronic Pain, No. (%)
Yes
No
Sleep disturbance, No. (%)
6-7 times/week
3-5 times/week
1-2 times/week
Never or less than once/week
Smoking Status, No. (%)
Current smoker
Former smoker
Never smoker
Alcohol Consumption, No. (%)
Regular Drinker
Occasional Drinker
Non-Drinker
Neurodegenerative Disease, No. (%)
Memory Problem, No. (%)
Macular Degeneration, No. (%)
Cardiovascular Condition, No. (%)
Stroke, No. (%)
Diabetes, No. (%)

1439 (6.4)
16057 (81.0)
2382 (10.7)
17819 (89.3)
6859 (33.3)
13342 (66.7)
2272 (10.9)
2458 (12.5)
3263 (16.6)
12208 (60.0)
1721 (8.8)
8783 (41.0)
9697 (50.2)
15725 (79.3)
2347 (10.4)
2129 (10.3)
213 (1.0)
257 (1.2)
757 (2.8)
3020 (12.5)
735 (2.7)
3311 (14.2)

Hypertension, No. (%)
7121 (30.3)
Cancer, No. (%)
2934 (11.5)
Osteoarthritis, No. (%)
3770 (15.7)
Sensory Impairment, No. (%)
3126 (14.6)
Neuropsychiatric Condition, No. (%)
5814 (29.6)
Respiratory Condition, No. (%)
3253 (15.6)
a
Means, standard errors, medians, IQRs, and percentages estimated using (trimmed) inflation weights.
Notes: AFT=Animal Fluency Test; CESD-10=Center for Epidemiologic Studies Depression Scale; HDL=
High Density Lipoprotein; hsCRP=high sensitivity C-Reactive protein; IQR=interquartile range; MAT=
Mental Alternation Test; PASE=Physical Activity Scale for the Elderly; SE=standard error.
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5.4.2 Correlates of Gait Speed: Bivariate Associations
The bivariate relationships between gait speed and its potential correlates are presented in
Table 5-3. Additional details are provided below.

5.4.2.1 Sociodemographic Correlates
Age was significantly negatively associated with gait speed. Next, being female was
associated with slower gait speed, with men and women walking at average speeds of
1.02 m/s (95% CI=1.01; 1.02) and 1.00 m/s (95% CI=0.99; 1.01) respectively.
Identifying as non-White was also associated with slower gait speed compared to those
who identified as White, with the White and non-White racial groups walking at average
speeds of 1.01 m/s (95% CI=1.01; 1.02) and 0.97 m/s (95% CI=0.96; 0.99) respectively.
Finally, compared to the post-secondary degree/diploma education group, lower levels of
education were associated with slower gait speeds. The mean gait speed for those with a
post-secondary degree/diploma was 1.02 m/s (95% CI=1.02; 1.02) while those with some
post-secondary education and those who only graduated secondary school had mean gait
speeds of 0.99 m/s (95% CI=0.98; 1.00) and 0.98 m/s (95% CI=0.97; 0.99) respectively.
The mean gait speed for individuals with less than a secondary school graduation was
0.90 m/s (95% CI=0.89; 0.92).

5.4.2.2 Anthropometric & Clinical Correlates
Height was positively associated with gait speed whereas weight was negatively
associated. Both Vitamin D (square root transformed) and HDL were positively
associated with gait speed while hsCRP (natural log transformed) was negatively
associated.
Depressive symptoms (CESD-10) were negatively associated with gait speed, while grip
strength was positively associated. Chronic pain was associated with slower gait speed
compared to those who reported being free of chronic pain, with mean gait speeds of 1.03
m/s (95% CI=1.02; 1.03) for those usually free of pain and 0.98 m/s (95% CI=0.98; 0.99)
for those with chronic pain. Trouble getting to the bathroom on time was also associated
with slower gait speed compared to those who reported no trouble, with an average
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walking speed of 0.94 m/s (95% CI=0.93; 0.95) for the group who reported trouble and
1.02 m/s (95% CI=1.02; 1.02) for the group who reported having no trouble. For sleep
disturbance, only reporting waking up and having difficulty falling back asleep 6 or 7
times per week was significantly associated with slower gait speed compared to those
who reported sleep disturbance occurring less than once per week or never, with mean
gait speeds of 1.00 m/s (95% CI=0.99; 1.01) for the 6-7 times per week group and 1.01
m/s (95% CI=1.01; 1.02) for the reference group.

5.4.2.3 Cognitive Correlates
High performance in immediate and delayed recall, verbal fluency, and attention were
significantly associated with faster gait speed. Stroop (interference) scores were
negatively associated with gait speed showing that a larger difference between the time
taken to complete the first (easiest) and third (hardest) trials of the Stroop test was
associated with slower gait speeds.

5.4.2.4 Lifestyle Behaviour Correlates
Higher physical activity (PASE) was positively associated with gait speed. Compared to
never smoking, being a current or former smoker was associated with slower gait speeds.
Never-smokers, current smokers, and former smokers walked at average speeds of 1.03
m/s (95% CI=1.02; 1.03), 0.98 m/s (95% CI=0.97; 0.99), and 1.00 m/s (95% CI=0.99;
1.00) respectively. Finally, report of regularly or occasionally drinking alcohol in the last
12 months was associated with faster gait average speeds compared to never drinking,
with the mean gait speeds of regular drinkers, occasional, and non-drinkers being 1.02
m/s (95% CI=1.02; 1.02), 0.98 m/s (95% CI=0.97; 0.99), and 0.97 m/s (95% CI=0.96;
0.98) respectively.

5.4.2.5 Chronic Condition Correlates
All non-modifiable and potentially modifiable chronic conditions were each significantly
negatively associated with gait speed. Those who reported that they had a
neurodegenerative disease, memory problem, or macular degeneration had average gait
speeds of 0.92 m/s (95% CI=0.88; 0.96), 0.93 m/s (95% CI=0.90; 0.96), and 0.95 m/s
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(95% CI=0.93; 0.96) respectively while the groups who reported not having these
conditions all had average gait speeds of 1.01 m/s (all 95% CIs=1.01; 1.02). Participants
who reported a history of stroke had a mean gait speed of 0.91 m/s (95% CI=0.89; 0.93),
while those without a stroke history had a mean gait speed of 1.01 m/s (95% CI=1.01;
1.02). Participants who reported having hypertension had a mean gait speed of 0.97 m/s
(95% CI=0.96; 0.97), while those who reported no hypertension walked at an average
speed of 1.03 m/s (95% CI=1.03; 1.03)
Those who reported that they had cancer, any neuropsychiatric condition, or any
respiratory condition had average gait speeds of 0.98 m/s (95% CI=0.97; 0.99), 1.00 m/s
(95% CI=0.99; 1.01), and 1.00 m/s (95% CI=0.99; 1.01) respectively. The groups who
reported not having cancer, any neuropsychiatric condition, or any respiratory condition
all had average gait speeds of 1.02 m/s (all 95% CIs=1.01; 1.02). Finally, participants
who reported any cardiovascular condition, osteoarthritis, diabetes, or any sensory
impairment had mean gait speeds of 0.94 m/s (95% CI=0.94; 0.95), 0.96 m/s (95%
CI=0.95; 0.96), 0.96 m/s (95% CI=0.96; 0.97), and 0.98 m/s (95% CI=0.97; 0.99)
respectively. The groups who did not report a cardiovascular condition, osteoarthritis,
diabetes, or a sensory impairment all had mean gait speeds of 1.02 m/s (95% CIs=1.02;
1.02/ 1.02; 1.03/ 1.02; 1.02/ 1.01; 1.02 respectively).
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Table 5-3. Bivariate associations between gait speed and selected factors.
B (95% CI)a

p

Age, years
Province, ON (Ref)
AB
BC
MB
NL
NS
QC
Sex, Male (Ref)
Female
Race, White (Ref)
Non-white
Highest Education Level, Post-secondary degree
or diploma (Ref)
Some post-secondary
Secondary only
Less than secondary
Anthropometric Factors

-.005 (-.006; -.005)

<.001
<.001

Height, m
Weight, kg
Chronic Conditions

.285 (.254; .315)
-.001 (-.001; -.001)

<.001
<.001

Neurodegenerative Disease
Memory Problem
Macular Degeneration
Cardiovascular Condition
Stroke
Diabetes
Hypertension
Cancer
Osteoarthritis
Respiratory Condition
Sensory Impairment
Neuropsychiatric Condition
Cognitive Factors

-.092 (-.128; -.056)
-.085 (-.113; -.056)
-.065 (-.082; -.048)
-.076 (-.085; -.068)
-.103 (-.121; -.085)
-.056 (-.064; -.048)
-.062 (-.068; -.056)
-.034 (-.043; -.026)
-.064 (-.071; -.056)
-.015 (-.022; -.009)
-.037 (-.045; -.028)
-.015 (-.022; -.009)

<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001

REY I (Immediate Recall)
REY II (Delayed Recall)
AFT
MAT
Stroop (Interference), sec

.014 (.012; .015)
.010 (.009; .011)
.006 (.006; .007)
.004 (.003; .004)
-.005 (-.005; -.004)

<.001
<.001
<.001
<.001
<.001

.028 (.022; .034)
.003 (.001; .004)
-.030 (-.033; -.027)
-.005 (-.006; -.005)

<.001
.001
<.001
<.001

Variable
Sociodemographic Factors

-.020 (-.031; -.006)
.035 (.026; .043)
-.036 (-.047; -.026)
-.052 (-.064; -.041)
.081 (.068; .093)
.007 (-.002; .016)
-.015 (-.021; -.010)
<.001
-.039 (-.057; -.022)
<.001
-.034 (-.045; -.023)
-.037 (-.046; -.027)
-.116 (-.130; -.103)

Clinical Factors
HDL, mmol/L
Vitamin D (square root), mmol/L
hsCRP (natural log), mg/L
Depressive symptoms (CESD-10)
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Trouble getting to bathroom on time
Chronic Pain
Grip Strength, kg
Sleep disturbance, Never or less than once/week
(Ref)
6-7 times/week
3-5 times/week
1-2 times/week
Lifestyle Factors

-.085 (-.095; -.075)
-.045 (-.051; -.038)
.003 (.003; .003)

<.001
<.001
<.001
.011

-.011 (-.021; -.001)
.007 (-.002; .016)
.007 (-.001; .015)

Physical Activity (PASE)
.0004 (.0003; .0004)
<.001
Smoking Status, Never (Ref)
Current Smoker
-.043 (-.054; -.032)
<.001
Former Smoker
-.031 (-.037; -.024)
Alcohol Consumption, Never (Ref)
Regular Drinker
.046 (.036; .057)
<.001
Occasional Drinker
.004 (-.009; .018)
a
Bivariate parameter estimates (B) for each independent factor obtained using complex samples general
linear model analysis (with analytic sampling weights) with gait speed (m/s) as the dependent variable.
Notes: HDL=High Density Lipoprotein; hsCRP=high sensitivity C-Reactive protein; AFT=Animal Fluency
Test; MAT=Mental Alternation Test; CESD-10=Center for Epidemiologic Studies Depression Scale;
PASE=Physical Activity Scale for the Elderly.

5.4.3 Potentially Modifiable and Non-Modifiable Correlates of Gait
Speed: Hierarchical Regression
The relationships between gait speed and the non-modifiable and potentially modifiable
factors in the five hierarchical regression models are presented in Table 5-4. Inclusion of
the two sets of non-modifiable factors alone explained 15.6% of gait speed variability.
Cognitive factors, potentially modifiable chronic conditions, and other potentially
modifiable clinical and lifestyle factors explained an additional 0.8%, 0.7%, and 2.6% of
variability respectively. The R2 for the final model was 19.7%.
Several potentially modifiable factors were statistically significantly associated with gait
speed in the final regression model. The chronic conditions that were significantly
negatively associated with gait speed were cardiovascular condition (B= -.018, 95% CI=
-.026; -.010), stroke (B= -.025, 95% CI= -.041; -.009), and osteoarthritis (B= -.012, 95%
CI= -.019; -.005). In terms of serum factors, (sqrt) Vitamin D concentration was
positively associated with gait speed (B= .003; 95% CI= .002; .005), and (log) hsCRP
concentration was negatively associated (B= -.003; 95% CI= -.007; -.0002).
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Having less than secondary school graduation was also significantly associated with
slower gait speed (B= -.030, 95% CI= -.043; -.017) as was being a current smoker (B=
-.027; 95% CI= -.038; -.017). Contrarily, physical activity (PASE score) was positively
associated with gait speed (B=.0001; 95% CI= .00005; .0001). Several potentially
modifiable clinical factors were also significantly associated with gait speed. Depressive
symptoms (CESD-10 score) were negatively associated with gait speed (B= -.003, 95%
CI= -.003; -.002), while grip strength was positively associated (B=.003; 95% CI= .002;
.003). Reporting chronic pain (B= -.011; 95% CI= -.017; -.005) or trouble getting to the
bathroom on time (B= -.031; 95% CI= -.040; -.022) were both negatively associated with
gait speed.
Cognitive tests for memory, executive function, and verbal fluency were significantly
associated with gait speed as well. Better performance on immediate recall (REY I) was
positively associated with gait speed (B=.003; 95% CI=.001; .005) along with
performance on tests of verbal fluency [AFT] (B=.002; 95% CI= .001; .002) and
executive function [MAT] (B= .0009; 95% CI= .0005; .001).

5.4.3.1 Sensitivity Analysis
To account for potential selection bias as a result of listwise exclusion of missing cases,
the models were re-run with missing cases imputed (Appendix F, Table F-1). Overall, the
imputed parameter estimates were of similar magnitude and direction. The only notable
change was that two potentially modifiable chronic conditions that were not initially
statistically significant (diabetes and sensory impairment) became so in the imputed
sample.
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Table 5-4. Hierarchical regression analysis of non-modifiable and potentially
modifiable correlates of gait speed.
Model 1a
[R (%) =11.8%]
2

Variable
Constant
Age, years
Sex, female
Province, ON (Ref)
AB

B (95% CI)
1.323 (1.305; 1.342)
-.005 (-.005; -.005)
-.014 (-.020; -.009)

P
<.001
<.001
<.001

-.028 (-.040; -.016)

<.001

BC
.034 (.026; .043)
MB
-.031 (-.041; -.021)
NL
-.059 (-.070; -.047)
NS
.077 (.065; .089)
QC
.010 (.002; .019)
Race, White (Ref)
Non-White
-.058 (-.075; -.041)
Education, Post-secondary degree or diploma (Ref)
Some post-secondary
-.020 (-.031; -.010)
Secondary education only
-.025 (-.034; -.016)
Less than secondary school graduation
-.078 (-.091; -.064)
Model 2
[R2 (%) =15.6%; R2 change = 3.8%]
Variable
B (95% CI)

<.001
<.001
<.001
<.001
.020

Constant
.728 (.644; .812)
Age, per year
-.005 (-.005; -.005)
Sex, female
.012 (.004; .021)
Province, ON (Ref)
AB
-.031 (-.043; -.019)
BC
.026 (.018; .035)
MB
-.025 (-.035; -.015)
NL
-.051 (-.062; -.040)
NS
.081 (.069; .093)
QC
.013 (.004; .022)
Race, White (Ref)
Non-White
-.051 (-.068; -.035)
Education, Post-secondary degree or diploma (Ref)
Some post-secondary education
-.014 (-.024; -.004)
Secondary education only
-.017 (-.026; -.008)
Less than secondary school graduation
-.059 (-.073; -.046)
Height, m
.432 (.386; .478)
Weight, kg
-.002 (-.002; -.002)
Neurodegenerative Disease
-.073 (-.107; -.040)
Memory Problem
-.067 (-.093; -.041)
Macular Degeneration
-.007 (-.022; .009)
Model 3
[R2 (%) = 16.4%; R2 change = 0.8%]
Variable
B (95% CI)

<.001
<.001
.003

Constant
Age, years
Sex, female
Province, ON (Ref)

<.001
<.001
.024

.655 (.570; .741)
-.004 (-.004; -.004)
.009 (.001; .018)

<.001
<.001
<.001
<.001

P

<.001
<.001
<.001
<.001
<.001
.003
<.001
.009
<.001
<.001
<.001
<.001
<.001
<.001
.390

P
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AB
-.031 (-.043; -.019)
BC
.024 (.016; .032)
MB
-.023 (-.033; -.013)
NL
-.048 (-.059; -.036)
NS
.085 (.073; .097)
QC
.019 (.010; .028)
Race, White (Ref)
Non-White
-.039 (-.043; -.019)
Education, Post-secondary degree or diploma (Ref)
Some post-secondary education
-.010 (-.021; .0002)
Secondary education only
-.010 (-.019; -.002)
Less than secondary school graduation
-.044 (-.057; -.031)
Height, m
.402 (.355; .448)
Weight, kg
-.002 (-.002; -.002)
Neurodegenerative Disease
-.070 (-.104; -.037)
Memory Problem
-.058 (-.084; -.032)
Macular Degeneration
-.007 (-.022; .008)
REY I (Immediate Recall)
.004 (.002; .006)
REY II (Delayed Recall)
-.002 (-.004; -.0002)
AFT
.002 (.001; .003)
MAT
.001 (.001; .001)
Stroop (Interference), sec
-.001 (-.001; -.0001)
Model 4
[R2 (%) = 17.1%; R2 change = 0.7%]
Variable
B (95% CI)
Constant
.671 (.585; .756)
Age, years
-.004 (-.004; -.003)
Sex, female
.010 (.002; .019)
Province, ON (Ref)
AB
-.031 (-.043; -.019)
BC
.024 (.016; .032)
MB
-.023 (-.033; -.013)
NL
-.049 (-.060; -.038)
NS
.084 (.072; .096)
QC
.020 (.011; .028)
Race, White (Ref)
Non-White
-.038 (-.055; -.022)
Education, Post-secondary degree or diploma (Ref)
Some post-secondary education
-.009 (-.020; .001)
Secondary education only
-.010 (-.019; -.002)
Less than secondary school graduation
-.039 (-.053; -.026)
Height, m
.374 (.328; .420)
Weight, kg
-.002 (-.002; -.002)
Neurodegenerative Disease
-.064 (-.098; -.031)
Memory Problem
-.046 (-.072; -.020)
Macular Degeneration
-.003 (-.018; .013)
REY I (Immediate Recall)
.004 (.002; .006)
REY II (Delayed Recall)
-.002 (-.004; -.0001)
AFT
.002 (.001; .003)
MAT
.001 (.001; .001)
Stroop (Interference), sec
-.0004 (-.001; -.000004)
Cardiovascular Condition
-.024 (-.031; -.016)
Stroke
-.032 (-.049; -.015)
Diabetes
-.011 (-.019; -.003)

<.001
<.001
<.001
<.001
<.001
<.001
<.001
.054
.022
<.001
<.001
<.001
<.001
<.001
.366
<.001
.026
<.001
<.001
.014

P
<.001
<.001
.015
<.001
<.001
<.001
<.001
<.001
<.001
<.001
.076
.021
<.001
<.001
<.001
<.001
.001
.739
<.001
.036
<.001
<.001
.048
<.001
<.001
.004
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Hypertension
Cancer
Osteoarthritis
Sensory Impairment
Neuropsychiatric Condition
Respiratory Condition

-.007 (-.013; -.001)
.0003 (-.008; .008)
-.018 (-.025; -.011)
-.014 (-.021; -.006)
-.013 (-.019; -.007)
-.007 (-.014; .001)

.022
.945
<.001
.001
<.001
.069

Model 5
[R2 (%) = 19.7%; R2 change = 2.6%]
B (95% CI)
.668 (.581; .755)
-.003 (-.003; -.002)
.050 (.040; .061)

P
<.001
<.001
<.001

-.034 (-.046; -.022)
.024 (.016; .032)
-.019 (-.028; -.009)
-.051 (-.062; -.040)
.086 (.074; .097)
.019 (.011; .028)

<.001
<.001
<.001
<.001
<.001
<.001

-.026 (-.043; -.010)

.002

-.004 (-.014; .006)
-.006 (-.015; .002)
-.030 (-.043; -.017)
.247 (.199; .295)
-.002 (-.002; -.001)
-.049 (-.082; -.016)
-.031 (-.056; -.006)
.002 (-.013; .018)
.003 (.001; .005)
-.002 (-.004; -.0002)
.002 (.001; .002)
.0009 (.0005; .001)
-.0002 (-.001; .0002)
-.018 (-.026; -.010)
-.025 (-.041; -.009)
-.003 (-.011; .004)
-.006 (-.012; .0001)
.003 (-.005; .010)
-.012 (-.019; -.005)
-.006 (-.013; .002)
-.0008 (-.007; .005)
-.0006 (-.008; .007)
.003 (-.004; .010)
.003 (.002; .005)
-.003 (-.007; -.0002)
-.003 (-.003; -.002)
-.031 (-.040; -.022)
-.011 (-.017; -.005)
.003 (.002; .003)

.425
.161
<.001
<.001
<.001
.003
.017
.747
.004
.033
<.001
<.001
.359
<.001
.003
.411
.059
.494
.001
.164
.803
.870
.460
<.001
.039
<.001
<.001
<.001
<.001

.007 (-.003; .016)
.007 (-.001; .016)

.153
.093

Variable
Constant
Age, years
Sex, Female
Province, ON (Ref)
AB
BC
MB
NL
NS
QC
Race, White (Ref)
Non-White
Education, Post-secondary degree or diploma (Ref)
Some post-secondary education
Secondary education only
Less than secondary school graduation
Height, m
Weight, kg
Neurodegenerative Disease
Memory Problem
Macular Degeneration
REY I (Immediate recall)
REY II (Delayed recall)
AFT
MAT
Stroop (Interference), sec
Cardiovascular Condition
Stroke
Diabetes
Hypertension
Cancer
Osteoarthritis
Sensory Impairment
Neuropsychiatric Condition
Respiratory Condition
HDL, mmol/L
Vitamin D (square root), mmol/L
hsCRP (natural log), mg/L
Depressive Symptoms (CESD-10)
Trouble getting to bathroom on time
Chronic Pain
Grip Strength, kg
Sleep disturbance, Never or less than once/week (Ref)
6-7 times/week
3-5 times/week
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1-2 times/week
.004 (-.003; .012)
.244
Physical Activity (PASE)
.0001 (.00005; .0001)
<.001
Smoking Status, Never (Ref)
Current Smoker
-.027 (-.038; -.017)
<.001
Former Smoker
-.008 (-.014; -.003)
.004
Alcohol Consumption, Never Drinker (Ref)
Regular Drinker
.016 (.006; .025)
.001
Occasional Drinker
.009 (-.003; .020)
.158
a
Analytic sampling weights applied in hierarchical regression analysis.
Notes: AFT=Animal Fluency Test; CESD-10=Center for Epidemiologic Studies Depression Scale; HDL=
High Density Lipoprotein; hsCRP=high sensitivity C-Reactive protein; MAT=Mental Alternation Test;
PASE=Physical Activity Scale for the Elderly.

5.5 Discussion
This study estimated the associations of non-modifiable and potentially modifiable risk
factors with gait speed in a large representative sample of community-dwelling middle
and older aged adults and estimated the amount of variation in gait speed that could be
explained by potentially modifiable factors. To our knowledge, this is one of the first
such studies.

5.5.1 Variation in Gait Speed is Largely Explained by Non-Modifiable
Factors
Our study demonstrated that in community-dwelling adults, nearly 16 percent of variation
in gait speed was explained solely by the blocks of non-modifiable factors (i.e.
sociodemographic and anthropometric factors, non-modifiable chronic conditions).
Potentially modifiable factors (i.e. cognitive measures, clinical factors, modifiable
chronic conditions, lifestyle behaviours) also significantly explained about four percent
of gait speed variability.
It is well understood that average gait speed is strongly influenced by multiple nonmodifiable biological factors including age and height.33–35 Recently, research has also
shown that gait disturbances are a hallmark of progressive neurodegenerative diseases
which involve the degeneration of neural structures directly involved in motor control
along with brain regions associated with cognitive functions that are essential for
maintaining normal gait.36
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The variability in gait speed explained by potentially modifiable factors further provides
evidence that gait speed is a complex motor function not solely determined by age and
other unalterable characteristics. Rather, it can be thought of as the product of a
multifactorial set of etiological factors acting through a network of pathophysiological
pathways.37 Following this paradigm, isolated factors may insufficiently explain
variations in gait speed; however, when considered as part of an interactive system, their
effects may be clearer and more substantial. Ultimately, applying this multidimensional
approach is crucial to gain a more complete understanding of the correlates of gait speed,
and to further mitigate abnormal declines in gait speed that indicate underlying morbidity
not associated with natural biological processes.38

5.5.2 Gait Speed is Significantly Associated with Multiple Potentially
Modifiable Factors
Several potentially modifiable factors were significantly associated with gait speed in the
final regression model. The chronic conditions that were significantly negatively
associated with gait speed in the final regression model including osteoarthritis, stroke,
and any cardiovascular condition. Previous studies have found that older adults with
osteoarthritis tend to walk slower and are more likely to experience gait speed declines as
a result of the mobility-impairing symptoms.39,40 However, with intervention,
improvement of functionality and quality of life is possible.41 Significant negative
associations between history of stroke and gait speed in older adults have been previously
reported,9,42,43 although findings are not consistent.10,44 The significant result we found
for having any cardiovascular disease (i.e. heart disease, myocardial infarction, angina,
peripheral vascular disease) also conflicts with many non-significant findings in the
literature,10,44,45 which may suggest that the directionality of this relationship is reversed,
with slower gait speed predicting adverse cardiovascular events instead.46 Regardless,
prevention of strokes and cardiovascular conditions through clinical intervention, lifestyle
modification, and education may partially mitigate detrimental mobility impairments and
subsequent morbidity in at-risk individuals.47,48
Having below a secondary school education was also significantly negatively associated
with gait speed. Analyses of socioeconomic disparities within communities have
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demonstrated that individuals with fewer years of education are more likely to become
disabled, engage in negative health behaviours, and face greater barriers to accessing
essential health care services including lacking adequate health literacy skills.49–51 While
only 4% of CLSA participants had not completed high school, the significant association
of low education level with gait speed in this cohort highlights the importance of
improving graduation rates in socioeconomically disadvantaged groups.
The negative association we found for smoking is consistent with previous studies,10,52,53
and supports arguments for the detrimental effects of smoking on physiological systems
underlying mobility.54 The positive association of alcohol consumption on gait speed in
our sample is also in line with other investigations,52,55 however a plausible explanation
for this finding is that individuals who can tolerate alcohol may simply be healthier and
more mobile than those who do not drink. It is also well understood that engaging in
physical activity across the adult lifespan promotes cardiovascular health and improves
muscle strength and our finding contributes to the growing body of literature
demonstrating the benefits of active lifestyles on walking speed in older age.56,57
We additionally found a significant positive association for serum vitamin D and a
significant negative association for C-reactive protein. This supports previous findings
that lower vitamin D levels and higher C-reactive protein levels are linked to slower gait
speed in older adults,

22,23,58–60

and ultimately highlights the importance of considering

the roles of these and other biomarkers in the multifactorial causality of gait impairments.
Grip strength, depressive symptoms, chronic pain, and trouble getting to the bathroom on
time were also significantly associated with gait speed. Weaker grip strength has been
linked to mobility declines.16,61 Although many older adults experience natural agerelated muscle loss, this can be mitigated through various lifestyle changes including
regular physical activity.62 Next, while we found an inverse cross-sectional association
between number of depressive symptoms and gait speed, longitudinal investigations have
suggested potentially bidirectional and reversed relationships.63,64 Models of the
biological pathways shared by depression and gait impairments have been proposed,65
and comorbid issues may further partially explain their relationship.66
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Chronic pain interferes with physical function and participation in everyday activities.
Although definitions of pain vary, studies generally report significant associations with
slower gait speed in adults, reinforcing the importance of pain management in mobility
decline mitigation efforts.9,10,18,67–69 Likewise, research has suggested that incontinence –
both bowel and urinary – can impose severe burdens on wellbeing. Evidence for the
correlation between urinary incontinence specifically with gait speed is conflicting,70,71
and this relationship may instead be reversed or bidirectional since slow walking can
hinder one’s ability to travel to the bathroom in a timely fashion and fear of incontinence
can contribute to mobility limitations as affected individuals feel less comfortable
engaging in regular daily activities.72
Finally, we found significant positive associations for most of the cognitive tests (i.e.
REY, AFT, MAT). Researchers have argued that multiple cognitive domains play
important roles in the motor control of initiation, maintenance, and adaptability of gait.73
Thus, impairments in cognition can lead to the development of gait abnormalities.74
Given the relationship between cognition and gait, implementing strategies to bolster
cognitive performance throughout the adult lifespan may impart benefits on mobility well
into older age.
It must be noted that many of the associations found for the potentially modifiable factors
highlighted above appeared to be small to moderate in magnitude. Although the use of
the large CLSA sample for this study offered the power to detect statistically significant
associations, the clinical significance of these results remains unclear. Ultimately,
consideration of the results in terms of their clinical meaningfulness in addition to their
statistical associations is necessary should they be referenced in the future in efforts to
define optimal targets for intervention to maintain healthy gait speed.

5.5.3 Limitations
This study has several limitations. Due to the cross-sectional design, we were not able
assess the directionality of the associations between the selected correlates and gait speed
or analyze gait speed changes prospectively. People were excluded from the CLSA based
on several geographic factors as well (e.g. residence in the territories, First Nations
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settlements/ reserves, or farther than 25-50 km from data collection sites), and the
majority who were recruited into the study were community-dwelling, White, highly
educated, and relatively healthy – all of which may limit the generalizability of the results
to other adult populations.
Next, the measurement of chronic conditions was done by self-report. Although selfreport has been shown to be a reliable and valid method to obtain information about
chronic conditions, individuals may have had undiagnosed conditions that they were not
aware of at the time of assessment, and self-report diagnoses do not incorporate severity
or response to treatment. Several composite variables combining similar conditions were
also created to simplify the analyses (e.g. cardiovascular conditions, neuropsychiatric
conditions). By doing so, some detail on the associations of specific conditions with gait
speed may have been lost.
Lastly, a non-exhaustive set of correlates was used for this analysis. We did not measure
the effects of other clinical factors possibly associated with gait speed such as
polypharmacy, falls, or musculoskeletal injuries. We also were unable to include other
social determinants of health – including access to medical care or social support – that
play major roles in healthy aging.

5.5.4 Conclusion
In this cross-sectional analysis of over 20,000 middle and older-aged Canadians, we
found associations of non-modifiable and potentially modifiable factors with gait speed.
We showed that while the variation in gait speed was largely explained by nonmodifiable factors, multiple factors were potentially modifiable, including education,
chronic pain, muscle strength, and cardiovascular conditions. We provide a framework
for future longitudinal analyses of gait speed and its complex determinants and
preliminary evidence to inform potential intervention strategies in at-risk adult
populations.
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Chapter 6

6 Summary and Conclusion
6.1 Overview
The objective of this chapter is to summarize the research and results presented in this
thesis and contextualize the findings within previous literature. Research and
methodological contributions are discussed along with limitations of the studies
conducted. Directions for future research and overall conclusions are also outlined.

6.2 Summary of Main Findings
The main goal of this thesis was to contribute to the growing body of literature seeking to
understand gait speed variations across the adult lifespan and identify the demographic,
clinical, and behavioural factors that may underlie these gait speed variations in older
age. By systematically reviewing current available literature, evidence for the effects of
multiple potentially modifiable risk factors on slow and declining gait speed was
synthesized (Chapter 2), providing a framework for an additional analysis of gait speed
correlates in a cohort of middle and older-aged community-dwelling Canadian adults
(Chapter 5). To complement the analysis of gait speed correlates, normative gait speed
data and the prevalence of slow gait were also estimated in this Canadian cohort to
describe the differences that exist across age and biological sex (Chapter 4).

6.2.1 Modifiable Risk Factors for Slow Gait in Community-Dwelling
Older Adults: A Systematic Review
The objective of the systematic review presented in Chapter 2 was to identify potentially
modifiable factors associated with slow gait speed and clinically meaningful gait speed
decline in older community-dwelling adults. In total, 40 studies met the inclusion criteria
and were qualitatively synthesized. Across these cross-sectional and longitudinal studies,
which were deemed fair or good quality, sample sizes ranged from 108 to 7025
participants and usual gait speed was measured using walk test distances ranging from
2.4 meters to 20 meters. Multiple different criteria were used to define slow gait and
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meaningful gait speed decline, with cutoffs being based either on sample distributions
(e.g. quartiles), external criteria (e.g. < 0.8 m/s), or dynamic changes over time (e.g. ≥
0.05 m/s decline per year). Due to the heterogeneity in these criteria and other
methodological factors, the slow gait prevalence estimates reported in the studies varied
widely, with frequencies ranging from 1.56% to 65.8%. Overall, 85 potentially
modifiable risk factors were assessed for an association with slow gait or meaningful gait
speed decline. Of these, 26 factors were assessed in at least two studies. Factors were
organized into the following groups for qualitative synthesis: sociodemographic, clinical,
lifestyle, body composition, serum, cognitive, and dietary.
Among the sociodemographic factors, education level was the only factor assessed in
multiple studies. Most studies that included education level in their analyses reported
significantly greater odds of slow gait or meaningful decline for adults who attained
lower levels of education (e.g. less than high school). Thirteen clinical factors were also
identified in at least two studies including depression, pain, multimorbidity, hypertension,
heart conditions, stroke, polypharmacy, falls, fear of falling, grip strength, arthritis,
diabetes, impaired vision. Most studies that assessed depression, pain, and polypharmacy
found that these conditions significantly increased the odds of slow gait while stronger
grip strength was found to be protective against slow gait. In general, effects reported for
multimorbidity, hypertension, heart conditions, and diabetes were non-significant, and
the effects reported for history of stroke, falls, fear of falling, arthritis, and vision
impairments were mixed.
Lifestyle factors that were assessed in multiple studies were physical activity, smoking,
and alcohol consumption. Many studies found that engaging in physical activity was
protective against slow gait. Non-significant effects were reported for smoking, and
inconsistent findings were reported for alcohol consumption. Among the body
composition variables, BMI, calf circumference, and bone mineral density were assessed
in multiple studies. Many studies reported significant associations between obese BMI
and greater odds of slow gait and some reported significant negative effects for
underweight BMI as well. Greater calf circumference was found to be significantly
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associated with lower odds of slow gait while effects for bone mineral density were
mixed.
Three serum factors were also assessed in multiple studies: vitamin D, high sensitivity CReactive Protein, and albumin. Effects reported for these factors were inconsistent,
however some studies found that lower vitamin D and elevated C-Reactive protein were
significantly associated with greater odds of slow gait. Cognitive factors that were
assessed in multiple studies were performance on the digit symbol substitution and trail
making tests. Higher scores on the digit symbol substitution test were found to be
associated with lower odds of slow gait cross-sectionally, however non-significant effects
were reported for performance on the trail making test. Finally, among the dietary factors,
Mediterranean diet was the only factor assessed in at least two studies. Both studies
reported that greater adherence to a Mediterranean diet reduced the odds of slow gait,
however different measurement tools were used to assess diet adherence.
Because of the heterogeneity in defining slow gait and meaningful gait speed decline and
the small amount of studies examining many of the identified factors, definitive
conclusions about factor effects could not be drawn. Despite this, the review was
successful in showing that the causes of slow gait and meaningful gait speed decline are
complex and multifactorial and provided valuable information for subsequent analyses.

6.2.2 Normative Values of Gait Speed among Middle and Older-Aged
Adults: An Analysis of Data from the Canadian Longitudinal
Study on Aging
Due to the complex processes underlying its production, gait speed is a marker of health
and functional ability. In order for timed walking tests to be useful in determining
whether older adults have or are at risk for developing impairments, normative values
outlining expected ranges of performance must be available for reference. The primary
objective of the Chapter 4 analysis was to estimate the normative values of usual (i.e.
self-selected) gait speed by age and biological sex using nationally representative
baseline data of 29,700 adults aged 45 to 85 years from the Canadian Longitudinal Study
on Aging Comprehensive cohort. Using these values, an example demonstrating the
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transformation of an individual’s gait speed into a population percentile was presented to
show the applicability of the normative data in a real-world clinical setting. The final
objective of Chapter 4 was to estimate the prevalence of ‘slow gait’ using multiple cutpoint ranges to describe the distribution of gait speed impairments across middle and
older adulthood.
Calculation of descriptive gait speed data by sex and age revealed that for both men and
women, average usual gait speeds were slower among the oldest age groups (i.e. 65-74
and 75+ years) compared to the younger age groups (i.e. 45-54 and 55-64 years). In
general, men had faster average gait speeds compared to women regardless of age,
however when standardized by height, the average gait speeds of women appeared faster.
Prevalence estimates for slow gait also revealed age-related trends. Notably, a greater
proportion of men and women in the two oldest age groups walked slower than a
‘normal’ speed (i.e. <1.0 m/s) compared to those aged 45-54 and 55-64 years. Among the
two oldest age groups, the majority of adults had gait speeds greater or equal to 0.8 m/s
but less than 1.0 m/s. Additionally, the proportions of men and women aged 75+ years
with gait speeds below 0.6 m/s were more than triple that seen in the 65-74 year age
groups.
Much of the discussion surrounding the normative values obtained in this study focused
on potential reasons why the average gait speeds of the CLSA participants appeared
slower than those of older adults from other studies presenting normative values. It was
suggested that sampling eligibility criteria (e.g. inclusion of adults with mild/moderate
physical impairments) and elements of the walk test protocol employed (e.g. allowed use
of assistive devices) were likely contributors to these slower average walking speeds.
Given that many other studies providing gait speed norms have employed stricter
participant inclusion criteria (e.g. healthy, able to walk unassisted), their values may not
be truly representative of the older adult populations they are seeking to describe. Thus,
the values obtained from the CLSA may be more appropriate references.
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6.2.3 Associations between Reversible Risk Factors and Gait Speed
in Middle and Older-Aged Community-Dwelling Adults: Results
from the Canadian Longitudinal Study on Aging
Using the baseline data from the CLSA Comprehensive cohort as well, Chapter 5 sought
to examine the demographic, clinical, and lifestyle correlates of usual (i.e. self-selected)
gait speed among middle and older adults. The amount of variation in gait speed
explained by these factors, which were classified as either non-modifiable or potentially
modifiable, was estimated, and the associations between individual potentially modifiable
factors and gait speed were also examined.
In total, 20,201 adults aged 45 to 85 years were included in the analysis. Using
hierarchical multivariable linear regression models, the sets of non-modifiable factors
(i.e. demographics, anthropometric factors, and non-modifiable chronic conditions) were
found to explain a greater proportion of gait speed variability than the potentially
modifiable factors (i.e. cognitive factors, modifiable chronic conditions, other modifiable
clinical and lifestyle factors), although all factor sets explained a significant proportion of
variance regardless of the amount. Several potentially modifiable factors were found to
be significantly associated with gait speed as well. These factors included low education
level, smoking, physical activity, any cardiovascular condition, stroke, osteoarthritis,
serum vitamin D, high sensitivity C-Reactive protein, depressive symptoms, grip
strength, chronic pain, and having trouble getting to the bathroom on time.
Overall, this study confirmed previous findings that non-modifiable biological factors
play a large role in gait speed. However, the results showed that these factors did not
entirely explain gait speed variations, which supports the idea that gait speed is a
multifactorial function that is also influenced by factors that can potentially be changed
through clinical intervention and lifestyle modification. Ultimately, this study is a
preliminary step toward developing models to longitudinally analyze gait speed and its
determinants using prospective data such as those collected from future CLSA waves and
improving current gait speed impairment mitigation strategies.
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6.3 Research and Methodological Contributions
Gait speed a fundamental component of mobility that allows individuals to travel through
variable environments and independently engage in daily activities. As gait speed is the
product of many complex bodily processes, underlying illnesses and impairments
affecting these processes can result in abnormal gait speed declines that can be
detrimental in older age.1 To effectively mitigate these harmful declines, it is important to
identify and intervene on factors in earlier adulthood that can be changed through clinical
treatment and lifestyle modification.2 The research presented in this thesis adds new
evidence confirming that although gait speed is inevitably influenced by age, it is also
affected by a multifactorial set of factors including those that can be modified. Taken
together, the findings presented in Chapters 2, 4 and 5 demonstrate the necessity of
standardized methods to effectively assess gait speed and its determinants and highlight
possible avenues for future prospective analyses of the etiology of gait speed declines
that can inform current clinical practices.
Chapter 2 provides a synthesis of the potentially modifiable risk factors associated with
slow and slowing gait speed among older adults. To our knowledge, the topic of this
systematic review was novel and is relevant given that research on gait impairments in
older adults has been expanding significantly with the recent growth of older populations.
Although this was only a qualitative review, the findings provide valuable information
about the roles that various types of risk factors may have in the incidence of slow gait
speed. By examining the reported factor effects, this review suggests areas that may be
worth investigating further in future prospective studies and intervention trials, and other
areas that may not be as promising. Along with risk factor identification, this review also
emphasized the heterogeneity in current methods used to operationalize slow and slowing
gait. As slow and slowing gait were defined based on many different cutoff criteria (i.e.
sample distribution, external criteria, dynamic change), the estimated prevalence of slow
and slowing gait varied widely across the included studies and the effects reported for the
risk factors were not directly comparable. This finding ultimately demonstrates the need
for uniform cutoffs to obtain prevalence estimates that are more reflective of true
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population characteristics and risk factor effect values that are comparable between
studies.
Next, Chapter 4 contributes normative gait speed estimates and slow gait prevalence
estimates among community-dwelling adults in a Canadian context. These descriptive
analyses add informative evidence to existing literature seeking to explain gait speed
trends across the adult lifespan, which currently lacks analyses of large, nationally
representative samples of adults. The significant gait speed trends we observed between
men and women across age groups were consistent with the findings of previous
research; however, differences in the average gait speed values obtained were evident and
most likely due to the implementation of varying methodologies between the CLSA and
traditional studies on gait speed norms.3–5 By using a more inclusive sample and less
restrictive protocols, the normative gait speed values obtained from the CLSA may
reflect the gait function of older adults more accurately and serve as a more realistic
reference for clinicians and researchers administering walking tests to assess the
functional ability of older adults, especially in Canadian contexts. Next, by estimating the
prevalence of slow gait using multiple operational definitions, we were also able to
examine the extent of impairment severity across the adult lifespan among Canadians. As
demonstrated in Chapter 2, many studies employ single, heterogeneous cutoffs to
dichotomize individuals as having ‘slow’ gait or ‘normal’ gait speed. This single cutoff
method not only leads to inconsistent slow gait prevalence estimates across studies,6–8 but
also results in a loss of detail about the full spectrum of gait speed impairment. The
application of several discrete ranges of gait speed for prevalence estimation in our study
demonstrates the usefulness of this method not only for simply describing the degrees of
gait speed function across sex and age groups but also for identifying meaningful trends
across these groups which may require further investigation to elucidate underlying
causes and indicate when interventions may be more appropriate to mitigate gait speed
impairment.
Finally, Chapter 5 expands on previous studies that have investigated the associations
between non-modifiable and potentially modifiable factors and gait speed. To our
knowledge, this is the first study to conduct such an investigation using a large
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representative sample of community-dwelling Canadian adults. Unlike previous studies
which have mainly focused on the individual associations between risk factors and gait
speed, our study also offers a wider picture of the varying contributions of nonmodifiable and potentially modifiable factors together on gait speed variability. In doing
so, this study was able to demonstrate the multifactorial nature of gait speed in real life
and highlights the importance of considering the roles that different types of potentially
modifiable factors may have in adult gait speed production beyond the effects of nonmodifiable factors such as aging. Along with characterizing the explanatory nature of
grouped factors on gait speed variability, using a hierarchical regression allowed us to
examine the associations between individual potentially modifiable factors and gait speed
after statistically adjusting for the effects of several non-modifiable factors. The
associations found were generally in line with previous studies of older adults, supporting
current understanding of prominent gait speed correlates that may be optimal targets for
interventions to mitigate gait speed impairments. While this study only presents crosssectional evidence like many others in the literature,9–11 the results provide a basis for
future longitudinal modelling of gait speed determinants using robust datasets such as the
CLSA. This additional work is essential as researchers continue striving toward a better
understanding of the multifactorial etiology of gait speed impairments.

6.4 Limitations
While informative, the research presented in this thesis has several limitations. First, only
observational studies were included in our systematic review since this design is most
practical for measuring the effects of modifiable risk factors on the risk of slow gait and
meaningful gait speed decline. Observational designs are often associated with greater
risks for biases that can be imposed during sampling and variable measurement, and
when missing data is present. While most of the studies included in this review were
deemed to be fair or good quality, these biases and other methodological issues could
have impacted the validity and generalizability of their results. Another limitation of this
review was that meta-analyses of the risk factors identified were not conducted. Along
with generally lacking a sufficient number of studies to analyze for many of the risk
factors, there was also a large amount of heterogeneity in methods used to measure slow
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gait/meaningful gait speed decline across the studies (i.e. differing walk test protocols,
differing cutoff values for outcome operationalization). This ultimately reduced the
comparability of effects between the studies.
Next, limitations were imposed by the cross-sectional nature of the analyses in Chapters 4
and 5. In Chapter 4, the estimation of normative gait speed values was restricted to a
single time point. While trends in the gait speed norms could be examined between men
and women of differing ages at this time point, assessment and comparison of between
and within-participant gait speed declines longitudinally was not possible, which would
have provided greater detail regarding the nature of gait speed at the individual level over
the adult lifespan. In Chapter 5, conclusions regarding the temporality of the relationships
observed between the selected demographic, clinical, and lifestyle correlates and gait
speed could not be drawn definitively. Although the cross-sectional relationships seen
between the selected correlates and gait speed may hold true, the factors that had
significant effects may contrarily have bidirectional or reversed relationships with gait
speed in real life.
The type of walk test employed in the CLSA to measure gait speed may have also
influenced the study findings, especially in Chapter 4 where the estimated gait speed
norms appeared slower than those previously published. While different types of walk
tests are generally reported to reliably produce similar walking speeds, variations in
protocol can still impact the speeds at which adults appear to walk and lead to
misrepresentation of their actual walking speeds outside of clinical research settings.12 In
the case of the CLSA, a shorter distance test with a static start was used; thus,
acceleration and deceleration times at the start and end of the walking test were not fully
accounted for. Participants were also allowed to use assistive devices to complete the
walk test which may further correlate with slower walking speeds.
There are other limitations surrounding the analysis in Chapter 5. Measurement of several
variables included as potential correlates of gait speed relied on some form of self-report
(e.g. chronic conditions, physical activity). These methods have been validated for use in
adult populations, however assessors must assume that participants have accurately and
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truthfully recalled the required information and errors in reporting can potentially
introduce bias. Also, while we attempted to include important, more commonly
investigated variables in our models, we acknowledge that there are other factors that
may also play a significant role in the gait speed of older adults that could not be included
in the regression analysis.
A final noteworthy limitation linking both Chapters 4 and 5 involves the use of large
sample sizes. Large samples inherently have more statistical power to detect statistically
significant relationships compared to small samples at the same Type I error probability.
While this allowed us to find significant associations in our analyses of gait speed norms
and gait speed correlates, many of the effects appeared small or moderate. Ultimately,
interpretation of these findings is cautioned as these statistically significant results may
not translate into effects that are clinically meaningful.

6.5 Directions for Future Research
Together, the studies in this thesis provide a strong basis for future research on gait speed
and its determinants in older adults. Although efforts to study modifiable gait speed
determinants have continuously expanded over the last several decades, syntheses of the
findings of this research remain scarce. By systematically reviewing a wide range of
potentially modifiable risk factors associated with slow and declining gait speed, we have
highlighted many factors that should be investigated further using robust prospective
studies to better understand their true effects on gait speed impairment. Additionally,
through our synthesis we showed that future studies on slow and declining gait speed
should consider employing multiple cutoffs to operationalize these outcomes to ensure
consistency and comparability of results.
The findings reported in Chapters 4 and 5 also present frameworks for future longitudinal
modelling of gait speed in Canadian adults. Using the baseline gait speed norms of the
CLSA participants as a reference, additional studies can further model the gait speed
declines experienced by these participants at subsequent follow-up time points.
Particularly, trajectories of decline can be characterized and potentially be applied to the
development of clinical reference tools that can be used to identify patients experiencing
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abnormal declines in gait speed that require further investigated. The model of gait speed
correlates in Chapter 5 can also be used in the future to examine such correlates
longitudinally to establish the causal relationships seen cross-sectionally. If possible,
these longitudinal analyses can be adapted to include other factors that are emerging as
potential influencers of mobility, such as social determinants of health and clinical factors
like polypharmacy.
Many studies of gait speed and its associated factors were done outside of Canada and
unfortunately, the characteristics of these samples often limit their generalizability to
groups residing in other areas. Thus, our studies offer insights to the necessity of
conducting future research in Canadian contexts to understand the unique characteristics
of Canadians adults that influence their gait speed over their lifespan. Overall, future
research endeavors should focus on examining the clinical relevance of gait speed trends
and risk factor effects. In doing so, intervention and education tools can be enhanced to
optimally mitigate gait speed impairments earlier in life and reduce the risk of additional
adverse outcomes.

6.6 Conclusion
The main objective of this thesis was to examine the factors that influence gait speed and
the risk of slow and slowing gait in older community-dwelling adults. By synthesizing
the results of published studies that have investigated slow gait determinants, the
systematic review showed that there are many potentially modifiable factors that may
serve as useful targets for maintaining gait speed in older age. Furthermore, the two
additional studies describing gait speed trends and correlates among older adults in the
Canadian Longitudinal Study on Aging support previous findings that gait speed is
variable across the adult lifespan and is significantly influenced by both non-modifiable
and potentially modifiable factors. Ultimately, the results of all three studies shed light on
the need for robust longitudinal studies on gait speed to better understand the ways in
which it is influenced by these different factors. The findings can be used to inform
clinicians and researchers seeking to mitigate gait speed declines in adults and its
associated adverse outcomes. They can also be used to support the enhancement of

113

current practices and programs aimed at improving the health and independence of older
adults.
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Appendices
Appendix A Systematic Review Search Strategy
Table A- 1. Search strategies by database.
Concept

MEDLINE

EMBASE

CINAHL

Keywords

Gait Speed

exp Walking
Speed/

exp Walking
Speed/

MH “Walking
Speed”

Aged

exp Aged/

exp Aged/

MH “Aged+”

“walking speed” OR “gait
speed” OR “gait velocity” OR
“slow gait” OR “walk speed”
OR “walk velocity” OR
“walking velocity” OR “slow
walking” OR “gait decline”
OR “gait impairment” OR
“timed walk” OR “timed
walks” OR “timed walking”
OR “timed gait”
aged OR elderly OR senior
OR geriatric OR “older adults”
OR “older people” OR “older
persons” OR “older
individuals”
“community dwelling” OR
“community dwellers” OR
healthy OR “normal human”
OR “normal people” OR
“normal persons” OR “normal
individuals”
7699 (4352 after removing
duplicates)

CommunityDwelling

Total
Citations

exp Normal
Human/

2525

3813

1361
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Figure A- 1. Flow chart of study selection.
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Appendix B Quality of Included Studies
Table B- 1. Risk of bias assessment for included studies.
Criteria*

Study
1
Kyrdalen et al.
Montero-Odasso et al.
Nasimi et al.
Toyama et al.
Laclaustra et al.
Kwan et al.
Lassale et al.
Umegaki et al.
Xu et al.
Adachi et al.
Simonsick, Aronson
et al.
Taylor et al.
Simonsick, Schrack et
al.
Ayers et al.
Frison et al.
Shafie et al.
Gill et al.
Veronese et al.
Yokoyama et al.

2

3

4

5

6

7

8

9

10

11

12

13

14

Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Y
Y
Y
Y
Y
Y
N
NR
Y
Y
Y

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

N
Y
Y
N
Y
Y
N
N
N
N
N

N
Y
N
Y
Y
N
Y
N
N
N
Y

N
Y
N
Y
Y
N
Y
N
N
N
Y

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
NA

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

N
Y
N
Y
Y
N
Y
N
N
N
Y

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR

NA
Y
NA
N
N
NA
N
NA
NA
NA
Y

N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Y
Y

Y
Y

Y
NR

Y
Y

N
N

N
Y

N
Y

NA
Y

Y
Y

NA
Y

Y
Y

NR
NR

NA
N

Y
Y

Y
Y
Y
Y
Y
Y

Y
Y
Y
Y
Y
Y

Y
N
Y
Y
Y
NR

Y
Y
Y
Y
Y
N

N
N
N
N
N
N

Y
N
N
Y
Y
Y

Y
N
N
Y
Y
Y

Y
Y
Y
Y
N
Y

Y
Y
Y
Y
Y
Y

Y
N
N
Y
NA
Y

Y
Y
Y
Y
Y
Y

NR
Y
NR
NR
NR
NR

N
NA
NA
Y
N
N

Y
Y
Y
Y
Y
Y
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Garcia-Esquinas et al.
Naples et al.
Zeng et al.
Verghese et al.
Plouvier et al.
Rosano et al.
Tchalla et al.
Kirkness et al.
Lo-Ciganic et al.
Busch et al.
Kim et al.
Lana et al.
Leon-Munoz et al.
Wu et al.
Ruggero et al.
Hirani et al.
Thorpe et al.
Eggermont et al.
Yoshida et al.
Shardell et al.
Chu et al.

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

NR
NR
NR
Y
NR
NR
NR
Y
Y
Y
N
NR
Y
N
Y
Y
NA
NR
Y
Y
Y

N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

N
N
N
N
N
N
Y
N
N
N
Y
N
Y
N
N
N
N
N
N
Y
Y

Y
Y
N
Y
N
Y
N
N
Y
N
Y
Y
Y
N
N
N
Y
N
N
N
Y

Y
Y
N
Y
N
Y
N
N
Y
N
Y
Y
Y
N
N
N
Y
N
N
N
Y

Y
Y
N
N
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
N
Y
NA
Y
Y
N
NA

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Y
Y
N
Y
N
N
N
N
Y
N
Y
NR
Y
N
N
N
Y
N
N
N
Y

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR

N
Y
NA
Y
NA
N
NA
NA
Y
NA
N
N
Y
NA
NA
NA
Y
NA
NA
NA
Y

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

*Criteria are as follows:
1
Was the research question or objective in this paper clearly stated?
2
Was the study population clearly specified and defined?
3
Was the participation rate of eligible persons at least 50%?
4
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the
study prespecified and applied uniformly to all participants?
5
Was a sample size justification, power description, or variance and effect estimates provided?
6
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?
7
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?
8
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure
measured as continuous variable)?
9
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?
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10

Was the exposure(s) assessed more than once over time?
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?
12
Were the outcome assessors blinded to the exposure status of participants?
13
Was loss to follow-up after baseline 20% or less?
14
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?
NR=Not Reported; NA=Not Applicable
11
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Appendix C Characteristics of Studies Included in Systematic Review
Table C- 1. Summary of characteristics for studies with cross-sectional design.
Study &
Location

Sample
Size

Age (mean ±
SD or range)

%
Female

Gait Speed
Measurement

Nasimi et al.
(Iran)

501

70.4 ± 4.6

49.3

4m walk test

Toyama et al.
(Australia)

789

72-75

0

Xu et al.
(China)

2633
(group
≥60yr)

females ≥60:
68.13 ± 6.14
males ≥60:
68.86 ± 6.47

57.8

6m walk test,
fastest of two
trials
6m walk test

Criteria for
slow gait/
decline in
gait speed
< 0.8 m/s

Prevalence of
slow gait/
decline in gait
speed, N (%)
218 (43.5)

< 0.8 m/s

Baseline:
77 (10.0)

< 0.8 m/s

Males ≥60:
150 (14.8)
Females ≥ 60:
240 (17.1)

Modifiable Risk
Factors Assessed

Underweight
Calf circumference
Body fat
Visceral fat area
Fat-free mass
Protein
Bone mineral
content
Albumin
Triglycerides
Renal function
Physical activity
BMI
Education level
Smoking
Drinking
Sleep time
Dyslipidemia
Hypertension
Bone mineral
density
Central adiposity
Diabetes
Metabolic
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Zeng et al.
(China)

461

females: 69.2 ±
6.5
males: 71 ± 5.7

55.1

6m walk test

< 0.8 m/s

Males: 5.31%
Females: 7.50%

Tchalla et al.
(USA)

680

78.1 ± 5.4

62.4

< 0.8 m/s

168 (25.0)

Kyrdalen et al.
(Norway)

108

75-77

62

4m walk test,
fastest of two
trials
4m walk test

< 1.0 m/s

48 (44.4)

syndrome
Coronary heart
disease
Stroke
Tumor
Physical activity
Total energy intake
Protein intake
Urban residence
BMI
2+ comorbidities
Smoking
Drinking
Physical activity
Meals per day
Unstructured daily
routine
Hobby engagement
Self-rated health
Hypertension plasma VCAM-1
interaction
Education level
Impaired vision
BMI (Underweight,
Overweight)
Multimorbidity
Polypharmacy
Falls
Fear of falling
Depressive
symptoms
Trail Making test
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Umegaki et al.
(Japan)

447

72.3 ± 4.6

45.4

5m walk test

< 1.0 m/s

7 (1.56)

Adachi et al.
(Japan)

308

79.9 ± 3.6

100

10m walk test

< 1.0 m/s

41 (13.3)

Taylor et al.
(USA)

7025

65-85+

56.8

3m walk test,
fastest of two
trials

< 1.0 m/s

984 (14.0)

Kirkness et al.
(USA)

2648

White
American
women: 59.0 ±
8.0
African
American
women: 62.4 ±
9.1

100

20m walk test

< 1.0 m/s

236 (9.0)

Digit Symbol
Substitution
Logical Memory II
Grip strength
Mini Mental State
Examination
Trail Making test
Depression
Physical activity
Chronic pain
Education level
Dementia
Multimorbidity
BMI (healthy/
underweight,
overweight)
Access to medical
care
Annual income
Education level
Severe knee
osteoarthritis
Severe knee pain
Back pain
Diabetes
Hypertension
Cancer
Heart failure
Stroke
Ulcer
Asthma
Lung disease
Depression
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Frison et al.
(France)

982

65.6 - 86.5

59

6m walk test

Busch et al.
(Brazil)

1112

60-75+

60.3

3m walk test,
slower of two
trials

Wu et al.
(Taiwan)

2680

69.0 ± 8.0

52.6

4m walk test

Eggermont et
al.
(USA)
Yoshida et al.
(Japan)

585

70-97

63.4

803

75.7 ± 5.0

59.0

4m walk test,
fastest of two
trials
5m walk test

Lowest
quartile of
sample
(<0.63 m/s)
Lowest
quartile by
sex and
height
1. men
≤1.66m:
≤0.68m/s
2. men
>1.66m:
≤0.78m/s
3. women
≤1.52m:
≤ 0.63m/s
4. women
>1.52m: ≤
0.68m/s
Lowest
quartile by
sex
Men: <
0.75m/s
Women: <
0.63m/s
Lowest
quartile
(< 0.784 m/s)
Lowest
quartile
adjusted for

239 (24.3)

Plasma fatty acids

277 (24.9)

Education level
Impairments in
activities of daily
living
Cardiovascular
disease
Physical activity
Grip strength
COPD

NR

Dietary fiber intake

NR

Pain (tender point
count, number of
pain sites)
C-Reactive Protein

NR
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sex
Kwan et al.
(China)

263

77.1 ± 7.5

83.7

5m walk test

Hirani et al.
(Australia)

25D
subgroup:
1659
1,25D
subgroup:
1536
1005

70-85+

0

6m walk test,
mean of two
trials

55.8

4m walk test,
mean of 2 trials

55

10m walk test

46.0

3m walk test

Shardell et al.
(Italy)

Shafie et al.
(Singapore)

2192

Women: 75.6
± 7.6
Men: 74.2 ±
7.0
69.2 ± 0.1

Plouvier et al.
(France)

736

55-69

Lowest
quintile
adjusted for
sex (Men:
<0.89m/s;
Women:
<0.79 m/s)
Lowest
quintile
adjusted for
height

93 (35.4)

Mediterranean diet
Life-space
Social participation

436 (13.9)

Vitamin D

Lowest
quintile by
sex and
height
≥1 SD below
age & sex
means of
sample
(Two lowest
tertiles)
Men: < 1.25
m/s
Women: <
1.20 m/s

Women: 121
(22.2)
Men: 99 (22.9)

Vitamin D
Parathyroid
hormone

274 (12.5)

Education level
Employment status
Physical activity
Disability
Occupation class
and physical
demands
Physical activity
BMI (overweight,
obese)
Smoking
Cardiovascular
disorder
Musculoskeletal
disorder

485 (65.8)
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Ruggero et al.
(Brazil)

385

71.4 ± 5.7

64.4

4.6m walk test,
mean of three
trials

(K-means
cluster
method)
< 0.91m/s

75 (28.1)

Physical activity
Stroke
Diabetes
Urinary
incontinence
Fear of falling

Table C- 2. Summary of characteristics for studies with longitudinal designs.
Study &
Location

MonteroOdasso et
al.
(Canada)
Veronese
et al.
(Italy)
Kim et al.
(Japan)

Sample
Size

249

Length
of
followup
5 yrs

Age (mean ±
SD or
range)

%
Female

Gait Speed
Measurement

76.6 ± 8.6

63

6m walk test

4m walk test, best
performance of
two trials
11m walk test,
faster of two trials

1904

Avg 4.4
yrs

72.5 ±6.0

62.5

538

4 yrs

Nonsarcopenic

100

: 78.5 ± 2.3
Presarcopenic:

77.3 ± 2.0
Sarcopenic:
78.5 ± 2.4
Severe
sarcopenic:

80.0 ± 2.1

Criteria for
slow gait/
decline in
gait speed
< 0.8 m/s

Prevalence of
slow gait/decline
in gait speed, N
(%)
Baseline: 29
(13.0)

Modifiable Risk
Factors Assessed

< 0.8 m/s

NR

Hyperuricemia

< 1.0 m/s

137 (25.5)

BMI (underweight)
Bone mineral density
Calf circumference
Timed Up and Go
Albumin
Vitamin D
B 2-globulin
Hemoglobin A1c
High density
lipoprotein
Cystatin C

Polypharmacy
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Gill et al.
(USA)

2246

4 yrs

60.2 ±8.8

53.8

20m walk test

< 1.2 m/s

Rosano et
al.
(USA)

Total:
5888

5 yrs

75.1 ± 5.5

57.6

4.6 m walk test

1.Clinical: <
0.6 m/s

Gait
follow-up
subgroup

2.Subclinical
: 0.6-1.0 m/s

: 1019

Laclaustra
et al.
(Spain)

Lassale et
al.
(England)

1948

2437

Mean
3.5 yrs

10 yrs

68.4 ± 6.2

71.3 ± 7.8

51.5

56.5

2.44m walk test

2.4m walk test,
mean of two trials

1. < 2 on
SPPB gait
(<0.43 m/s or
couldn’t do)
2. lowest
quintile
adjusted for
sex, height
Lowest
quintile by
age and sex

Physical activity
Pain (general, knee)
Falls
Osteoporosis
Heart disease
Hyperlipidemia
Knee osteoarthritis
Follow-up: 400
BMI-waist
(15.1)
circumference
interaction
Baseline
Digit symbol
1. Clinical (< 0.6
substitution
m/s): 644 (10.9)
White matter
2. Subclinical (0.6- hypertensities
1.0 m/s): 3164
(53.7)
Follow-Up
1.Clinical (< 0.6
m/s): 130 (12.8)
2. Subclinical (0.61.0 m/s): 973
(95.5)
SPPB gait < 2:
293 (15.7)

Dietary
inflammatory index

Lowest quintile:
192 (12.4)

332 (14.9)

C-Reactive Protein
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ENRICA
cohort:
1872

ENRICA
cohort:
3.5yrs

ENRICA
cohort:
68.7±6.4

ENRICA
cohort:
51.6

AMI
cohort:
473

AMI
cohort:
2yrs

AMI cohort:
74.5 ±5.8

AMI
cohort:
37.8

3C
cohort:
581

3C
cohort:
12yrs

3C cohort:
81.8±4.1

3C cohort:
63.5

Lana et al.
(Spain)

1871

Mean
3.5 yrs

68.8 ± 6.3

51.3

3m walk test

LeónMuñoz et
al.
(Spain)

1815

Mean
3.5 yrs

68.5 ± 0.3

60.0

3m walk test

Ayers et al.
(USA)

LonGenity

LonGenity

cohort:
3 yrs

LonGenity
cohort:
75.21 ±6.4

LonGenity

8.5m walk test

cohort:
625
CCMA
cohort:
312

CCMA
cohort:
2 yrs

CCMA
cohort: 76.4
±6.87

CCMA
cohort:
56.7

2306

4 yrs

78.4 ± 0.83

61.4

GarcíaEsquinas et
al.
(France)

Verghese
et al.
(USA)

cohort:
53.3

3m walk test

lowest
quintile

ENRICA cohort:
279 (14.9)

Fruit/vegetable
consumption

AMI cohort :87
(18.4)
3C cohort:95
(16.4)

2.5 m walk test,
mean of two trials

Lowest
quintile
adjusted for
sex and
height
Lowest
quintile
adjusted for
sex and
height
≥1 SD below
age & sex
means of
sample

≥ 1 SD below
age-sex
means

NR

Dairy consumption

180 (9.9)

Mediterranean diet

Baseline:
1.LonGenity
cohort: 68 (10.9)
2.CCMA cohort:
47 (15.1)

Apathy (depressive
symptoms)

Follow-up:
1.LonGenity
cohort: 81 (14.5)
2.CCMA cohort:
22 (8.3)
Baseline: 691
(17.0)

Muscle weakness
(grip strength)
Cognitive
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1. < 70yrs:
< 0.57 m/s (F),
< 0.62 m/s
(M)

Follow-up: 243
(11.0)

2. 70-79yrs:
< 0.49 m/s
(F),
< 0.56 m/s
(M)
3.
80+ yrs:
< 0.38 m/s
(F),
< 0.45 m/s
(M)

Simonsick
et al.
(2018a)
(USA)
Simonsick
et al.
(2018b)
(USA)
Thorpe et
al.
(USA)

667

1-5 yrs
(mean
2.3 yrs)

60-89

50.8

6m walk test,
faster of two trials

579

1-4 yrs
(mean
2.2 yrs)

60-89

53.2

6m walk test,
faster of two trials

2969

5 yrs

70-79

51.5

6m walk test,
faster of two trials

Naples et
al.
(USA)

2402

4 yrs

74.6 ± 2.9

51.3

20m walk test

≥ 0.05m/s
decline in
gait speed
per year
≥ 0.05m/s
decline in
gait speed
per year
≥ 0.05m/s
decline in
gait speed
per year

Meaningful
decline at followup (%): 32.8%

1.≥ 0.1m/s
decline in
gait per year

% gait decline ≥
0.1 m/s per yr:
Yr 2-3: 22.4%
Yr 3-4: 22.6%
Yr 5-6: 23.9%

2.less than

Meaningful
decline at followup (%): 33.2
749 (31)

impairment
Pain
Vision impairment
Falls
Physical activity
BMI (obesity)
Drinking
Poor sleep quality
Arthritis
Stroke
Diabetes
Hypertension
Heart condition
Depression
Pain

Fatigability
(physical, mental)
Energy level
Tiredness
BMI (Obesity)
Arthritis (knee, hip)
Multimorbidity
Education level
Home ownership
Education level
Drug-disease/ drugdrug interactions
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Lo-Ciganic
et al.
(USA)

2405

4 yrs

74.6 ± 2.8

51

20m walk test

Yokoyama
et al.
(Japan)

779

4 yrs

71.5 ±5.0

46.7

5m walk test

Chu et al.
(China)

1419

1 yr

73.1 ± 6.2

49.5

5m walk test

median
speed
(< 1.15 m/s)
≥ 0.1m/s
decline in
gait per year
decline to the
lowest
baseline
quartile level
at follow-up
>1 SD
decline in
gait speed
from
baseline
value

Follow-up 1: 491
(22)
Follow-up 2: 452
(23)
Follow-up: 75
(11.9)

Statin use

Follow-up: 96
(7.2)

Vision impairment
Falls

Dietary variety
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Appendix D Overall Characteristics of CLSA
Comprehensive Cohort at Baseline
Table D- 1. Characteristics of the baseline CLSA Comprehensive cohort (N=30,097).
Variable

Measure

Age, years

Mean ± SE
(max, min)
Mean ± SE
(min, max)
Mean ± SE
(min, max)
Median,IQR
Mean ± SE
(min, max)
Median,IQR
Mean ± SE
(min, max)
Mean ± SE
(min, max)
Mean ± SE
(min, max)
Mean ± SE
(min, max)
Mean ± SE
(min, max)

Height, m
Weight, kg
Vitamin D, mmol/L

hsCRP, mg/L

HDL, mmol/L
Gait Speed, m/s
Grip Strength, kg
REY I
(Immediate Recall)
REY II
(Delayed Recall)
AFT
MAT
Stroop (Interference)
Depressive Symptoms
(CESD-10)
Physical Activity
(PASE)

Mean ± SE
(min, max)
Mean ± SE
(min, max)
Mean ± SE
(min, max)
Mean ± SE
(min, max)
Median,IQR
Mean ± SE
(min, max)
Median,IQR

Missing
n (%)

Original data,
Unweighted

Original
data,
Weighted

Imputed
data,
Weighted

-

62.9 ± 0.06
(45, 86)
1.7 ± 0.0005
(1.18, 2.04)
79.8 ± 0.10
(34.9, 198.85)
86.0, 48.0
89.7 ± 0.23
(8.0, 385.0)
1.2, 2.10
2.56 ± 0.031
(0.10, 162.3)
1.49 ± 0.003
(0.12, 4.45)
0.98 ± 0.001
(0.11, 2.56)
33.36 ± 0.069
(0.16, 84.1)
5.85 ± 0.011
(0, 14)

59.5 ± 0.061

-

1.69 ± 0.0006

1.69 ± 0.0006
(1.18, 2.04)
80.24 ± 0.12
(34.9, 198.85)
82.65, 47.33
86.83 ± 0.24
(8, 385)
1.12, 2.10
2.46 ± 0.03
(0.10, 162.3)
1.49 ± 0.003
(0.12, 4.45)
0.99 ± 0.001
(0.11, 2.56)
34.45 ± 0.08
(0.16, 84.1)
6.05 ± 0.01
(0, 14)

100 (0.3)
130 (0.4)
3100
(10.3)
3094
(10.3)
3093
(10.3)
392 (1.3)
2290
(7.6)
1020
(3.4)
1051
(3.5)
731 (2.4)
1486
(4.9)
424 (1.4)
161 (0.5)

1640
(5.4)

Mean ± SE
(min, max)
Sex
Female
Male
Province
Alberta

n (%)

n (%)

4.04 ± 0.013
(0, 14)
19.67 ± 0.033
(0, 47)
26.54 ± 0.05
(0, 51)
14.26 ± 0.049
(-83.0, 122.0)
4.0, 5.0
5.28 ± 0.027
(0, 30)
130.8, 96.1
141.06 ± 0.44
(0, 692.73)

80.23 ± 0.12
82.73, 47.22
86.93 ± 0.25
1.11, 2.00
2.44 ± 0.03
1.49 ± 0.003
0.99 ± 0.001
34.74 ± 0.08
6.06 ± 0.01
4.28 ± 0.02
20.30 ± 0.04
27.33 ± 0.06
13.12 ± 0.05
3.68, 5.51
5.24 ± 0.031
139.99,
104.13
150.70 ± 0.55

4.27 ± 0.014
(0, 14)
20.29 ± 0.038
(0, 47)
27.28 ± 0.06
(0, 51)
13.14 ± 0.05
(-83.0, 122.0)
3.69, 5.51
5.24 ± 0.031
(0, 30)
139.56, 0.68
150.39 ± 0.54

15320 (50.9)
14777 (49.1)

15301 (50.8)
14796 (49.2)

-

2957 (9.8)

2957 (9.8)

-

-
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Variable

British Columbia
Manitoba
Newfoundland and
Labrador
Nova Scotia
Ontario
Quebec
Race
White
Non-white
Level of Education
Less than secondary
school graduation
Secondary school
graduation only
Some post-secondary
education
Post-secondary degree
or diploma
Trouble getting to
bathroom on time
Yes
No
Chronic Pain
No
Yes
Sleep Disturbance
Never or < once/week
1-2 times/week
3-5 times/week
6-7 times/week
Smoking Status
Current smoker
Former smoker
Never smoker
Type of Drinker
Regular Drinker
Occasional Drinker
Non-Drinker
Neurodegenerative
Disease, Yes
Memory Problem, Yes
Macular Degeneration,
Yes
Cardiovascular
Condition, Yes
Stroke, Yes
Diabetes, Yes
Hypertension, Yes

Measure

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Missing
n (%)

Original data,
Unweighted
6254 (20.8)
3113 (10.3)
2214 (7.4)

Original
data,
Weighted
6254 (20.8)
3113 (10.3)
2214 (7.4)

Imputed
data,
Weighted
-

3078 (10.2)
6418 (21.3)
6063 (20.1)

3078 (10.2)
6418 (21.3)
6063 (20.1)

-

28771 (95.6)
1326 (4.4)

28610 (95.1)
1487 (4.9)

-

1643 (5.5)

1355 (4.5)

1360 (4.5)

2838 (9.4)

2628 (8.7)

2633 (8.7)

2236 (7.4)

2081 (6.9)

2084 (6.9)

23322 (77.6)

23989 (79.8)

24020 (79.8)

3927 (13.1)
26136 (86.9)

3353 (11.2)
26706 (88.8)

3359 (11.2)
26738 (88.8)

18127 (63.1)
10620 (36.9)

18551 (64.4)
10239 (35.6)

19330 (64.2)
10767 (35.8)

18169 (60.4)
4699 (15.6)
3604 (12.0)
3590 (11.9)

17967 (59.7)
4843 (16.1)
3727 (12.4)
3536 (11.8)

17982 (59.7)
4845 (16.1)
3730 (12.4)
3540 (11.8)

2710 (9.0)
13145 (43.7)
14242 (47.3)

2830 (9.4)
12234 (40.6)
15033 (49.9)

-

22598 (76.9)
3559 (12.1)
3222 (10.7)
357 (1.2)

23052 (76.6)
3697 (12.3)
3348 (11.1)
379 (1.3)

-

58 (0.2)

34 (0.1)

1350
(4.5)
35 (0.1)

-

734 (2.4)

n (%)

110 (0.4)

22231 (75.7)
3705 (12.6)
3427 (11.7)
390 (1.3)

n (%)
n (%)

102 (0.3)
214 (0.7)

519 (1.7)
1280 (4.3)

469 (1.6)
953 (3.2)

491 (1.6)
969 (3.2)

n (%)

450 (1.5)

4962 (16.7)

3982 (13.2)

4152 (13.8)

n (%)

261 (0.9)

1313 (4.4)

999 (3.3)

1060 (3.5)

n (%)
n (%)

110 (0.4)
179 (0.6)

5310 (17.7)
11101 (37.1)

4713 (15.6)
9724 (32.3)

4740 (15.7)
9792 (32.5)
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Variable

Measure

Missing
n (%)

Original data,
Unweighted
4637 (15.5)
5847 (19.8)
5180 (17.2)

Original
data,
Weighted
3789 (12.6)
5047 (16.7)
4766 (15.8)

Imputed
data,
Weighted
3806 (12.6)
5186 (17.2)
4773 (15.8)

Cancer, Yes
Osteoarthritis, Yes
Sensory Impairment,
Yes
Neuropsychiatric
Condition, Yes
Respiratory Condition,
Yes

n (%)
n (%)
n (%)

93 (0.3)
611 (2.0)
45 (0.1)

n (%)

217 (0.7)

8884 (29.7)

9069 (30.1)

9156 (30.4)

n (%)

250 (0.8)

5049 (16.9)

4954 (16.5)

5023 (16.7)
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Appendix E Characteristics of Analytical Sample versus
Excluded Group
Table E- 1. Comparison of characteristics for analytical sample and individuals
excluded from Chapter 5 analyses.
Variable

Analytic Sample with
Complete Data
(n=20,201)
58.84 ± 0.08
1.01 ± 0.002

Excluded Group with
Missing Data
(n=9,896)
60.95 ± 0.132
0.97 ± 0.003

Age, mean ± SE1
Gait speed, mean ± SE
Sex, No. (%)
Female
9971 (48.6)
5349 (54.2)
Male
10230 (51.4)
4547 (45.7)
Race, No. (%)
White
19479 (95.7)
9292 (92.4)
Non-white
722 (4.3)
604 (7.6)
Education, No. (%)
Less than secondary school graduation
910 (4.0)
733 (6.7)
Secondary school graduation only
1795 (8.6)
1043 (9.8)
Some post-secondary education
1439 (6.4)
797 (7.4)
Post-secondary degree or diploma
16057 (81.0)
7265 (76.1)
1
Means, standard errors, and percentages estimated using (trimmed) inflation weights.

P

< .001
< .001
< .001

< .001

< .001
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Appendix F Sensitivity Analysis – Hierarchical Regression
with Imputed Missing Data
Table F- 1. Hierarchical regression models with multiply imputed missing data.
Model 1
Variable
Constant
Age, years
Sex, female
Province, ON (Ref)
AB
BC
MB
NL
NS
QC
Race, White (Ref)
Non-White
Education, Post-secondary degree or diploma (Ref)
Some post-secondary education
Secondary education only
Less than secondary school graduation
Model 2

B (95% CI)1
1.346 (1.332; 1.362)
-.006 (-.006; -.005)
-.019 (-.024; -.014)

P
<.001
<.001
<.001

-.024 (-.035; -.015)
.036 (.028; .043)
-.033 (-.041; -.024)
-.057 (-.066; -.047)
.080 (.070; .090)
.008 (.0004; .015)

<.001
<.001
<.001
<.001
<.001
.038

-.069 (-.081; -.056)

<.001

-.022 (-.031; -.013)
-.028 (-.036; -.021)
-.072 (-.083; -.062)

<.001
<.001
<.001

Variable
Constant
Age, years
Sex, female
Province, ON (Ref)
AB
BC
MB
NL
NS
QC
Race, White (Ref)
Non-White
Education, Post-secondary degree or diploma (Ref)
Some post-secondary education
Secondary education only
Less than secondary school graduation
Height, m
Weight, kg
Neurodegenerative Disease
Memory Problem
Macular Degeneration
Model 3

B (95% CI)
.757 (.686; .828)
-.005 (-.005; -.005)
.007 (-.0001; .014)

P
<.001
<.001
.053

-.027 (-.037; -.018)
.028 (.021; .035)
-.028 (-.036; -.019)
-.049 (-.058; -.040)
.085 (.075; .095)
.011 (.003; .018)

<.001
<.001
<.001
<.001
<.001
.004

-.062 (-.074; -.050)

<.001

-.015 (-.024; -.006)
-.020 (-.027; -.013)
-.056 (-.067; -.045)
.431 (.392; .469)
-.002 (-.002; -.002)
-.079 (-.104; -.056)
-.070 (-.090; -.050)
-.019 (-.031; -.007)

.001
<.001
<.001
<.001
<.001
<.001
<.001
.002

Variable
Constant
Age, years

B (95% CI)
.678 (.606; .750)
-.004 (-.004; -.004)

P
<.001
<.001
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Sex, female
Province, ON (Ref)
AB
BC
MB
NL
NS
QC
Race, White (Ref)
Non-White
Education, Post-secondary degree or diploma (Ref)
Some post-secondary education
Secondary education only
Less than secondary school graduation
Height, m
Weight, kg
Neurodegenerative Disease
Memory Problem
Macular Degeneration
REY I (Immediate Recall)
REY II (Delayed Recall)
AFT
MAT
Stroop (Interference), sec
Model 4
Variable
Constant
Age, years
Sex, female
Province, ON (Ref)
AB
BC
MB
NL
NS
QC
Race, White (Ref)
Non-White
Education, Post-secondary degree or diploma (Ref)
Some post-secondary education
Secondary education only
Less than secondary school graduation
Height, m
Weight, kg
Neurodegenerative Disease
Memory Problem
Macular Degeneration
REY I (Immediate Recall)
REY II (Delayed Recall)
AFT
MAT
Stroop (Interference), sec
Cardiovascular Condition

.003 (-.004; .010)

.406

-.027 (-.037; -.017)
.026 (.019; .033)
-.025 (-.034; -.017)
-.044 (-.053; -.035)
.089 (.080; .099)
.018 (.011; .026)

<.001
<.001
<.001
<.001
<.001
<.001

-.047 (-.059; -.034)

<.001

-.011 (-.020; -.002)
-.012 (-.020; -.005)
-.038 (-.048; -.027)
.394 (.356; .433)
-.002 (-.002; -.002)
-.074 (-.098; -.050)
-.058 (-.077; -.038)
-.019 (-.031; -.007)
.005 (.003; .007)
-.002 (-.004; -.0006)
.002 (.001; .002)
.001 (.001; .001)
-.001 (-.001; -.0005)

.020
.001
<.001
<.001
<.001
<.001
<.001
.002
<.001
.010
<.001
<.001
<.001

B (95% CI)
.697 (.626; .769)
-.004 (-.004; -.003)
.004 (-.003; .011)

P
<.001
<.001
.239

-.028 (-.038; -.018)
.026 (.018; .033)
-.026 (-.034; -.018)
-.045 (-.054; -.036)
.088 (.079; .098)
.018 (.011; .025)
-.047 (-.059; -.034)

<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001

-.010 (-.018; -.001)
-.012 (-.019; -.004)
-.033 (-.043; -.022)
.360 (.321; .399)
-.002 (-.002; -.002)
-.064 (-.088; -.040)
-.039 (-.059; -.019)
-.013 (-.025; -.001)
.004 (.003; .006)
-.002 (-.004; -.0004)
.002 (.001; .002)
.001 (.001; .001)
-.0006 (-.001; -.0003)
-.025 (-.032; -.019)

.030
.002
<.001
<.001
<.001
<.001
<.001
.038
<.001
.013
<.001
<.001
<.001
<.001
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Stroke
Diabetes
Hypertension
Cancer
Osteoarthritis
Sensory Impairment
Neuropsychiatric Condition
Respiratory Condition

-.043 (-.055; -.031)
-.016 (-.022; -.009)
-.006 (-.011; -.0005)
.001 (-.005; .008)
-.022 (-.028; -.016)
-.016 (-.022; -.009)
-.014 (-.019; -.008)
-.008 (-.014; -.002)

<.001
<.001
.032
.739
<.001
<.001
<.001
.011

B (95% CI)
.710 (.637; .782)
-.003 (-.003; -.003)
.050 (.041; .058)

-.033 (-.045; -.020)

P
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001

-.006 (-.014; .003)
-.007 (-.014; -.00003)
-.023 (-.034; -.013)
.211 (.170; .251)
-.001 (-.001; -.001)
-.045 (-.068; -.021)
-.024 (-.043; -.004)
-.008 (-.020; .004)
.004 (.002; .005)
-.002 (-.003; -.0004)
.001 (.001; .002)
.001 (.001; .001)
-.0004 (-.001; -.00006)
-.018 (-.025; -.012)
-.034 (-.046; -.022)
-.007 (-.013; -.0003)
-.004 (-.009; .001)
.004 (-.002; .011)
-.015 (-.021; -.009)
-.007 (-.013; -.001)
.0004 (-.005; .005)
-.001 (-.007; .005)
.003 (.002; .004)
-.005 (-.008; -.002)
.001 (-.005; .008)
-.003 (-.003; -.002)
-.032 (-.039; -.024)
-.014 (-.019; -.009)
.003 (.002; .003)

.203
.049
<.001
<.001
<.001
<.001
.016
.180
<.001
.014
<.001
<.001
.021
<.001
<.001
.039
.111
.202
<.001
.029
.876
.789
<.001
<.001
.724
<.001
<.001
<.001
<.001

Model 5
Variable
Constant
Age, years
Sex, female
Province, ON (Ref)
AB
BC
MB
NL
NS
QC
Race, White (Ref)
Non-White
Education, Post-secondary degree or diploma (Ref)
Some post-secondary education
Secondary education only
Less than secondary school graduation
Height, m
Weight, kg
Neurodegenerative Disease
Memory Problem
Macular Degeneration
REY I (Immediate Recall)
REY II (Delayed Recall)
AFT
MAT
Stroop (Interference), sec
Cardiovascular Condition
Stroke
Diabetes
Hypertension
Cancer
Osteoarthritis
Sensory Impairment
Neuropsychiatric Condition
Respiratory Condition
Vitamin D (square root), mmol/L
hsCRP (natural log), mg/L
HDL, mmol/L
Depressive Symptoms (CESD-10)
Trouble getting to bathroom on time
Chronic Pain
Grip Strength, kg
Sleep Disturbance, Never or less than once/week (Ref)

-.030 (-.039; -.020)
.026 (.019; .033)
-.021 (-.029; -.013)
-.048 (-.057; -.039)
.090 (.080; .100)
.018 (.011; .025)
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6-7 times/week
.003 (-.005; .011)
.423
3-5 times/week
.007 (.001; .015)
.026
1-2 times/week
.004 (-.002; .011)
.148
Physical Activity (PASE)
.0001 (.0001; .0002)
<.001
Smoking Status, Never (Ref)
<.001
Current Smoker
-.023 (-.032; -.015)
<.001
Former Smoker
-.006 (-.010; -.001)
.020
Alcohol Consumption, Never (Ref)
Regular Drinker
.017 (.009; .025)
<.001
Occasional Drinker
.004 (-.006; .014)
.417
1
Analytic sampling weights applied in hierarchical regression analysis.
2
Abbreviations: AFT, Animal Fluency Test; CESD-10, Center for Epidemiologic Studies Depression Scale;
HDL, High Density Lipoprotein; hsCRP, high sensitivity C-Reactive protein; MAT, Mental Alternation
Test; PASE, Physical Activity Scale for the Elderly.
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